glycopyrrolate profile

Glycopyrrolate is a synthetic anticholinergic drug used to treat various conditions, including overactive bladder, chronic obstructive pulmonary disease (COPD), and Parkinson's disease. It is a quaternary ammonium compound that acts as a muscarinic antagonist, meaning it blocks the action of acetylcholine at muscarinic receptors in the body. Glycopyrrolate is typically administered orally or by inhalation.

Glycopyrrolate is often preferred over other anticholinergic drugs for its long duration of action and low incidence of side effects, such as dry mouth and blurred vision. However, like all drugs, it can have potential adverse effects, so it is important to talk to your doctor before taking glycopyrrolate.

Research on glycopyrrolate has been ongoing for several decades. Scientists have investigated its pharmacological properties, therapeutic applications, and potential benefits in various diseases. One area of focus is its use in COPD, where glycopyrrolate helps to relax airway muscles and improve airflow. Additionally, research is exploring glycopyrrolate's potential for treating other conditions such as Parkinson's disease and post-operative ileus.

Glycopyrrolate's synthesis involves multiple steps, starting with the preparation of the precursor molecule, tropine. Tropine is reacted with an appropriate acid chloride to form the glycopyrrolate ester. The final product is then purified and formulated for use in medications.'

Glycopyrrolate: A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycopyrronium bromide : A quaternary ammonium salt composed of 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium and bromide ions in a 1:1 ratio. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	11693
CHEMBL ID	1201027
CHEBI ID	90972
SCHEMBL ID	41436
MeSH ID	M0009495

Synonym
ahr 504
robinul forte
1-methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide
3-hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate
glycopyrrolate bromide
einecs 209-887-0
glycopyrronii bromidum
pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate
bromure de glycopyrronium [inn-french]
pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate
bromuro de glicopirronio [inn-spanish]
1,1-dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate
nsc 251251
glycopyrronii bromidum [inn-latin]
nsc 250836
nsc 251252
HMS3393P12
org-nc-45
cas-596-51-0
tarodyl
asecryl
ahr-504
robinal
glycopyrronium bromide
robinul
596-51-0
gastrodyn
nsc251251
nsc251252
nsc250836
.beta.-1-methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide
nodapton
glycopyrrolate
robanul
tarodyn
nva-237
MLS001424112
pt-001
smr000469282
cuvposa
seebri breezhaler
ad-237
chf-5992
3-hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate
nsc-250836
pyrrolidinium,1-dimethyl-, bromide
1,1-dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate
mandelic acid, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide
3-hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate
pyrrolidinium,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate
wln: t5ktj a1 a1 covxqr&- al5tj &q &e
1-methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide
nsc-251252
nsc-251251
glycopyrrolate (usp)
cuvposa (tn)
glycopyrronium bromide (jan/inn)
D00540
robinul (tn)
seebri breezhaler (tn)
MLS002222301
HMS2051P12
HMS2094A05
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
pt001
CHEMBL1201027
nva237
chf-5259
chf5259
glycopyrrone bromide
glycopyrronium (as bromide)
glycopyrrolate, erythro-
HMS1570E14
A832400
3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-ium bromide
NCGC00179456-02
HMS2097E14
HMS3259P04
nva 237
dtxsid6023109 ,
tox21_113144
dtxcid103109
tox21_113145
nsc759238
pharmakon1600-01505753
nsc-759238
HMS2235F12
S4660
AKOS015962136
CCG-101030
glycopyrrolate [usan:usp]
seebri
copyrrolate
lonhala magnair
bromuro de glicopirronio
bromure de glycopyrronium
seebri neohaler
FT-0626787
HMS3369F10
CCG-213543
HY-17465
CS-1763
NC00694
NC00280
SCHEMBL41436
NCGC00179456-04
tox21_113144_1
3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium bromide
CHEBI:90972
VPNYRYCIDCJBOM-UHFFFAOYSA-M
AC-23382
3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium bromide
G0392
mfcd00072137
SR-01000763650-3
sr-01000763650
glycopyrrolate, united states pharmacopeia (usp) reference standard
glycopyrronium for peak identification, european pharmacopoeia (ep) reference standard
glycopyrronium impurity n, european pharmacopoeia (ep) reference standard
glycopyrronium bromide, european pharmacopoeia (ep) reference standard
glycopyrrolate, >=98% (hplc)
HMS3714E14
BCP07110
Q27162963
glycopyrronium bromide ,(s)
AMY22352
glycopyrrolate erythro isomer (ss-isomer)
BCP33298
HMS3885P14
glycopyrronium (bromide);glycopyrrolate (bromide)
(2s,3's)-glycopyrrolate
pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-,bromide
EX-A4155
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
EN300-7405787
3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidin-1-ium bromide
pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide, [s-(r,s)]-
3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-iumbromide

Excerpt	Reference	Relevance
"Glycopyrrolate/eFlow® is an investigational drug-device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer."	( Dose selection for glycopyrrolate/eFlow Donohue, JF; Goodin, T; Tosiello, R; Wheeler, A, 2017)	1.5
"Glycopyrrolate (GLY) is an antimuscarinic agent that is used in humans and domestic animals primarily to reduce respiratory tract secretions during anesthesia and to reverse intra-operative bradycardia. "	( Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse. Hochhaus, G; Kandala, B; Rumpler, MJ; Sams, RA; Vickroy, TW, 2014)	2.11
"Glycopyrrolate is an antimuscarinic agent that can be used preoperatively to inhibit drooling and excessive secretions of the respiratory tract. "	( Glycopyrrolate for treatment of clozapine-induced sialorrhea in adults. Blissit, KT; Latham, C; Pacheco-Perez, J; Tillery, E, 2014)	3.29
"Glycopyrrolate seemed to be a tolerable anticholinergic agent in the treatment of clozapine-associated sialorrhea."	( The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. Cahn, W; Colen-de Koning, JC; Doodeman, HJ; Egberts, TC; Heerdink, ER; Man, WH; Schulte, PF; van Haelst, IM; Wilting, I, 2017)	1.54
"Oral glycopyrrolate is a cost-effective, painless second-line therapy for children and adolescents with primary focal hyperhidrosis that impacts their quality of life."	( Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. Chamlin, SL; Mancini, AJ; Paller, AS; Shah, PR; Silverio, AM; Wagner, A, 2012)	1.41
"Glycopyrrolate is a peripheral anti-muscarinic drug that has been studied in comparison to atropine for many clinical indications, while scopolamine is an anti-muscarinic drug with both peripheral and central effects."	( Adverse reaction to atropine and the treatment of organophosphate intoxication. Hourvitz, A; Luria, S; Robenshtok, E; Tashma, Z, 2002)	1.04
"Glycopyrrolate is a quaternary ammonium compound with indications for use similar to those for atropine. "	( [Glycopyrrolate (Robinul), a new anticholinergic substance]. Cozanitis, DA; Krieg, N, 1983)	2.62
"Glycopyrrolate is an effective anticholinergic agent in rabbits and rodents and more useful as a preanesthetic agent than atropine sulfate in these animals."	( The parasympatholytic effects of atropine sulfate and glycopyrrolate in rats and rabbits. Cox, AK; Morck, DW; Olson, ME; Vizzutti, D, 1994)	1.26
"Glycopyrrolate is an anticholinergic agent used to dry oral secretions and has been advocated for routine use with transesophageal echocardiography (TEE). "	( A double-blind trial of glycopyrrolate for transesophageal echocardiography. DiLucente, L; Gorcsan, J; Katz, WE; Thornton, JK; Ziady, GM, )	1.88
"Glycopyrrolate is an anti-muscarinic agent that can be applied topically and is efficacious in gustatory sweating occurring in other conditions."	( A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Abbott, CA; Boulton, AJ; Hollis, S; Shaw, JE; Tindle, K, 1997)	1.28
"Glycopyrrolate is a quaternary ammonium compound."	( Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. Olsen, AK; Sjøgren, P, 1999)	1.54
"Glycopyrrolate is a quaternary anticholinergic drug. "	( Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog. Bodor, N; Huang, F; Ji, F; Juhasz, A; Wu, W, 2000)	1.99
"Glycopyrrolate (Robinul) is a quaternary ammonium salt which serves as a respiratory enhancing drug. "	( Solid-phase extraction techniques for the determination of glycopyrrolate from equine urine by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. Beaumier, P; Firby, P; Leavitt, RK; Matassa, LC; Woodard, D, 1992)	1.97
"Glycopyrrolate is a quaternary ammonium anticholinergic compound that is poorly absorbed from mucus membranes, thus reducing anticholinergic side effects."	( Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. Bush, RK; Busse, WW; Chervinsky, P; Schroeckenstein, DC, 1988)	1.21
"Glycopyrrolate is an anticholinergic agent lacking central nervous system effects."	( Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). Halsall, PJ; Kelway, B; Simpson, KH; Smith, RJ, 1986)	1.3

Excerpt	Reference	Relevance
"Glycopyrrolate has a slow and erratic absorption from the gastrointestinal system, but even low plasma levels are associated with a distinct and long-lasting antisialogic effect."	( Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. Olsen, AK; Sjøgren, P, 1999)	1.54
"Glycopyrrolate has been treated to induce reversible hyposalivation for accelerating caries progression."	( Novel strategy for dental caries by physiologic dentin regeneration with CPNE7 peptide. Gug, HR; Jang, JY; Lee, DS; Lee, JH; Park, JC; Park, SJ; Park, YH; Shon, WJ, 2022)	1.44
"Glycopyrrolate has been successfully used to treat other types of hyperhidrosis."	( A medical alternative to the treatment of compensatory sweating. Callejas, MA; Cladellas, E; Grimalt, R, )	0.85
"As glycopyrrolate has been reported superior to atropine with respect to reduction of salivation, stability of cardiac rate and rhythm, and recovery, a comparison of these properties of the two drugs and placebo was made in 45 patients undergoing direct laryngoscopy and 45 patients undergoing bronchoscopy, in most cases followed by mediastinoscopy. "	( Glycopyrrolate vs. atropine during anaesthesia for laryngoscopy and bronchoscopy. Grønnebech, H; Johansson, G; Smedebøl, M; Valentin, N, 1993)	2.35
"Glycopyrrolate solution has the potential to deliver an ocular anticholinergic effect without causing associated central anticholinergic hazards."	( The mydriatic effect of topical glycopyrrolate. Haas, K; Lazar, M; Rothman, S; Varssano, D, 1996)	2.02
"Glycopyrrolate has a slow and erratic absorption from the gastrointestinal system, but even low plasma levels are associated with a distinct and long-lasting antisialogic effect."	( Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. Olsen, AK; Sjøgren, P, 1999)	1.54
"Glycopyrrolate has gained popularity and was the most used drug."	( Anticholinergic premedication in Finland 1988. Kanto, J; Kentala, E; Salonen, M, 1990)	1
"Glycopyrrolate has advantages over atropine as far as the induction of anaesthesia for microlaryngoscopic interventions is concerned."	( [Effect of glycopyrrolate and atropine on the behavior of heart rate and pH value of gastric juice during microlaryngoscopies]. Behne, M; Lischke, V; Mickel, A, 1988)	1.39

Excerpt	Reference	Relevance
"Glycopyrrolate blocked the increase in SDRRI (P < 0.001) and blunted spectral power at 0.15 Hz (P < 0.05)."	( Vagal modulation of heart rate variability during atrial fibrillation in pigs. Hamdan, MH; Kneip, CF; Mallet, RT; Smith, ML; Williams, AG, 2010)	1.08
"Glycopyrrolate decreased lower oesophageal sphincter pressure by 0.88 kPa (p less than 0.005)."	( The effect of glycopyrrolate (Robinul) on the lower oesophageal sphincter. Brock-Utne, JG; Dimopoulos, GE; Downing, JW; Moshal, MG; Rubin, J; Welman, S, 1978)	1.34

Excerpt	Reference	Relevance
"Glycopyrrolate has been treated to induce reversible hyposalivation for accelerating caries progression."	( Novel strategy for dental caries by physiologic dentin regeneration with CPNE7 peptide. Gug, HR; Jang, JY; Lee, DS; Lee, JH; Park, JC; Park, SJ; Park, YH; Shon, WJ, 2022)	1.44
"Glycopyrrolate successfully treated intraoperative penile erection. "	( Use of glycopyrrolate to treat intraoperative penile erection. Case report and review of the literature. Sang, CN; Valley, MA, )	2.03
"Treatment with glycopyrrolate resulted in significant improvements in all lung function measures, independent of smoking status. "	( Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Bowling, A; Goodin, T; Ozol-Godfrey, A; Price, B; Sanjar, S; Sharma, S; Tashkin, DP, 2019)	1.08
"Treatment with glycopyrrolate did not change pupil diameter or IOP from baseline, nor were there differences between glycopyrrolate and saline-treated (control) dogs."	( Parenteral anticholinergics in dogs with normal and elevated intraocular pressure. Bellay, Y; Brunson, DB; Frischmeyer, KJ; Miller, PE; Smedes, SL, )	0.47

Excerpt	Reference	Relevance
"Two recent studies have identified copious secretions as an independent risk factor for perioperative adverse events in children who present for elective surgery in the presence of an upper respiratory tract infection (URI)."	( Glycopyrrolate does not reduce the incidence of perioperative adverse events in children with upper respiratory tract infections. Burke, C; Chiravuri, D; Malviya, S; Tait, AR; Voepel-Lewis, T; Wagner, D, 2007)	1.78
" NVA237 was generally well tolerated and associated with a frequency and distribution of adverse events similar to placebo."	( Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Cheung, D; Galdiz, JB; Güçlü, SZ; Henley, M; Mizutani, G; Overend, T; Spangenthal, S; Verkindre, C; Vogelmeier, C; Zeldin, RK, 2010)	0.36
" Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo."	( Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. Dolker, M; Fabbri, LM; Horton, R; Martin, C; Overend, T; Van de Maele, B, 2010)	0.36
" NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical antimuscarinic adverse effects."	( Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Banerji, D; D'Urzo, A; Ferguson, GT; Hirata, K; Horton, R; Lu, Y; Martin, C; Overend, T; van Noord, JA, 2011)	0.37
"Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea, and health-related quality of life, and reduced the risk of exacerbations and the use of rescue medication."	( Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Banerji, D; D'Urzo, A; Ferguson, GT; Hirata, K; Horton, R; Lu, Y; Martin, C; Overend, T; van Noord, JA, 2011)	0.37
" Atropine and glycopyrrolate are anticholinergics that could reduce the adverse effects of imidocarb."	( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses. Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013)	1.11
"To compare glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses and to determine the effect of combinations of these drugs on the gastrointestinal tract."	( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses. Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013)	1.14
"Results of this study suggest that glycopyrrolate is superior to atropine in ameliorating the adverse effects of imidocarb."	( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses. Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013)	1.03
"Glycopyrrolate could be administered with imidocarb in horses with piroplasmosis to reduce the adverse effects of imidocarb."	( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses. Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013)	2.19
" Primary endpoint was safety and tolerability for treatment-emergent adverse events (AEs)."	( Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Alagappan, VK; Banerji, D; Chapman, KR; Chen, H; Dahl, R; Kho, P; Mehta, R; Rudolf, M, 2013)	0.39
"2% in the IND+GLY group experienced an adverse event, with the majority being mild-to-moderate in severity."	( Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Alagappan, VK; Banerji, D; Chen, H; Dahl, R; Jadayel, D, 2013)	0.39
" Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group."	( Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF, 2013)	0.39
" Adverse events were reported by a similar percentage of patients receiving glycopyrronium (40."	( A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. Bateman, ED; Beeh, KM; Beier, J; Chapman, KR; Chen, H; D'Andrea, P; D'Urzo, A; Henley, M; Nutbrown, R; Overend, T, 2014)	0.4
" Primary outcomes were trough FEV1, severe adverse events, and serious cardiovascular events."	( Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Plaza, V; Rodrigo, GJ, 2014)	0.4
" There were no deaths or serious adverse events."	( Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. Brown, M; Drollmann, A; Febbraro, S; Hara, H; Jones, I; Perry, S; Sechaud, R, 2014)	0.4
" The incidence of adverse events was similar for the two treatment groups."	( Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Aumann, J; Chen, H; Goyal, P; Henley, M; McBryan, D; Vincken, W, 2014)	0.4
" In the absence of a better alternative, salbutamol, a beta-2 agonist, or ipratropium, an antimuscarinic, are tried first, despite their adverse effects."	( Glycopyrronium for inhalation. COPD: another antimuscarinic with cardiac adverse effects that require monitoring. , 2014)	0.4
" Each evaluation included weighing sweat and assessing the Hyperhidrosis Disease Severity Scale (HDSS) score and any adverse effects."	( Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. Choi, HG; Hong, CK; Hyun, MY; Kim, BJ; Kim, MN; Lee, Y; Li, K; Park, KY; Seo, SJ; Son, IP, 2015)	0.7
" No serious adverse events were reported during the course of this study."	( Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. Choi, HG; Hong, CK; Hyun, MY; Kim, BJ; Kim, MN; Lee, Y; Li, K; Park, KY; Seo, SJ; Son, IP, 2015)	0.7
"Topical glycopyrrolate application appears to be significantly effective and safe in reducing excessive facial perspiration."	( Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. Choi, HG; Hong, CK; Hyun, MY; Kim, BJ; Kim, MN; Lee, Y; Li, K; Park, KY; Seo, SJ; Son, IP, 2015)	1.14
" All doses were safe and well tolerated in this study; the most frequently reported adverse event was dry mouth (0-14."	( Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. Darken, P; Fernandez, C; Fischer, T; Fogarty, C; Golden, M; Orevillo, C; Reisner, C; Rennard, S; Rose, ES; Tardie, G, 2014)	0.4
"This study demonstrated superior bronchodilatory efficacy of GP MDI compared with Placebo MDI at all doses tested, and no serious adverse events were reported."	( Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. Darken, P; Fernandez, C; Fischer, T; Fogarty, C; Golden, M; Orevillo, C; Reisner, C; Rennard, S; Rose, ES; Tardie, G, 2014)	0.4
" Overall hazard ratio (HR) was assessed between the active treatments and placebo and in various subgroups related to severity of airways obstruction, inhaled corticosteroid use, cardiovascular risk factors, sex, age and body mass index for death, serious cases of cardio- and cerebrovascular (CCV) events, major adverse cardiovascular events (MACEs), pneumonia, COPD exacerbations requiring hospitalisation or atrial flutter/fibrillation (AF/F)."	( Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Banerji, D; Buhl, R; Chen, H; D'Andrea, P; Dahl, R; Fogel, R; Schubert-Tennigkeit, A; Wedzicha, JA, 2014)	0.4
"All treatments were well tolerated with similar adverse event rates reported with placebo and at all doses."	( Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Barnes, PJ; Jones, CR; Leaker, BR; Singh, D; Tutuncu, A, 2015)	0.7
" Respiratory arrest is an uncommon side effect of glycopyrrolate with very few published reports."	( Glycopyrrolate-induced respiratory arrest: an unusual side effect. D'souza, S; Gowler, V, 2015)	2.11
" Overall incidence of adverse events (glycopyrronium 43."	( Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Bai, L; D'Andrea, P; Firth, R; Huang, Y; Humphries, M; Kho, P; Li, L; Sun, T; Wang, C; Wang, Q, 2015)	0.42
" The incidence of adverse events was comparable between both treatments (QVA149=43."	( Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Buhl, R; Foerster, K; Gessner, C; Hiltl, S; Korn, S; Schuermann, W; Sieder, C, 2015)	0.42
" Although this class of compounds is generally considered to be safe and well tolerated in COPD patients the cardiovascular safety of tiotropium has recently been questioned."	( Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Charlton, SJ; Collingwood, S; Ethell, BT; Kent, TC; Sykes, DA; Trifilieff, A; Watson, KJ, 2015)	0.42
" In most clinical trials the incidence of cardiovascular adverse events was similar in active treatment and placebo groups, especially in patients with previous cardiovascular diseases."	( [Are there cardiovascular adverse effects of inhaled anticholinergics?]. Nagy, LB, 2015)	0.42
"The overall incidence of adverse events and deaths was similar across groups, while the incidence of serious adverse events was numerically higher in placebo."	( Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. Altman, P; Chapman, KR; D'Andrea, P; D'Urzo, AD; Decramer, M; DiGiovanni, R; Goyal, P; Hu, H; Kerwin, EM, 2015)	0.42
" PSX1002-GB was well tolerated with similar adverse event rates reported compared to placebo."	( Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study. Buck, H; Down, G; O'Connor, G; Ravi, A; Reid, F; Singh, D, 2016)	0.43
" The primary objective was to assess the safety and tolerability in terms of adverse event (AE) reporting rates over 52 weeks."	( Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3). Banerjee, R; D'Andrea, P; Eckert, JH; Gifford, AH; Jessop, N; Mahler, DA; Mota, F; Satti, A, 2016)	0.76
" The incidence of major adverse cardiovascular events was low and comparable between the groups."	( Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3). Banerjee, R; D'Andrea, P; Eckert, JH; Gifford, AH; Jessop, N; Mahler, DA; Mota, F; Satti, A, 2016)	0.76
"Significant improvement in lung function, dyspnea, COPD symptoms, health status, and rescue medication use suggests that glycopyrrolate is a safe and effective treatment option as maintenance bronchodilator in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation."	( Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. D'Andrea, P; Eckert, JH; Feldman, G; Henley, M; LaForce, C; Patalano, F; Spangenthal, S, 2016)	0.92
"Drawing up atropine or glycopyrrolate at the beginning of the operating list and use within 24 hours if needed are a safe practice and do not pose infection hazard."	( Atropine and glycopyrrolate do not support bacterial growth-safety and economic considerations. Batai, I; Batai, IZ; Ittzes, B; Kerenyi, M; Weiling, Z, 2016)	1.11
" It also demonstrates a rare drug adverse effect with successful treatment."	( Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment. Fischer, R; Liu, D; Prouty, ME, 2016)	1.88
" Incidences of adverse events, serious adverse events and major adverse cardiovascular events were similar across treatment groups with no unexpected safety findings."	( Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Denenberg, M; Donohue, JF; Hanania, NA; Kerwin, EM; Maes, A; O'Donnell, DE; Orevillo, C; Quinn, D; Reisner, C; Siddiqui, S; Tashkin, DP, 2017)	0.74
" Neostigmine has good efficacy in the decompression of pseudo-obstruction but is hindered by its wide side effect profile."	( Neostigmine and glycopyrronium: a potential safe alternative for patients with pseudo-obstruction without access to conventional methods of decompression. Adiamah, A; Ho, A; Johnson, S; Orbell, J, 2017)	0.46
" Primary endpoints were the incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, and discontinuations due to TEAEs."	( Long-term safety of glycopyrrolate/eFlow Ferguson, GT; Goodin, T; Kerwin, E; Tosiello, R; Wheeler, A, 2017)	0.78
"Treatment with nebulized glycopyrrolate was well tolerated over 48 weeks with the most common adverse events being COPD worsening and cough."	( Long-term safety of glycopyrrolate/eFlow Ferguson, GT; Goodin, T; Kerwin, E; Tosiello, R; Wheeler, A, 2017)	1.08
" The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases."	( Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation. Bernardi, B; Bordoni, V; Borioni, E; Cesari, V; Cocci, G; Francioso, A; Giordano, P; Giulietti, F; Iacoacci, C; Landi, L; Lombardi, FE; Rosettani, G; Sarzani, R; Spannella, F, )	0.13
" Safety assessments included monitoring for adverse events (AEs)."	( Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. DePetrillo, P; Dorinsky, P; Maes, A; Reisner, C; Siddiqui, S, 2018)	0.48
" All GP MDI doses were well tolerated with no evidence of a dose-related effect on adverse events."	( Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial. Darken, P; Dorinsky, P; Duncan, EA; Kerwin, E; Nyberg, J; Reisner, C; Sher, L; Siddiqui, S; Wachtel, A, 2018)	0.48
" Treatment-emergent adverse events were similar between subgroups, and most were mild, transient, and infrequently led to discontinuation."	( Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Drew, J; Forsha, DW; Glaser, DA; Gopalan, R; Green, L; Hebert, AA; Pariser, DM; Werschler, WP, 2019)	0.51
" GT was well tolerated, and treatment-emergent adverse events were qualitatively similar between subgroups and consistent with other anticholinergics."	( Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Drew, J; Forsha, DW; Glaser, DA; Gopalan, R; Green, L; Hebert, AA; Pariser, DM; Werschler, WP, 2019)	0.51
" Treatment-emergent adverse events and local skin reactions were assessed."	( A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. Drew, J; Glaser, DA; Green, L; Hebert, AA; Mamelok, RD; Nast, A; Pariser, DM; Quiring, J; Werschler, WP, 2019)	0.51
" Most patients experiencing treatment-emergent adverse events had mild or moderate events (> 90%)."	( A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. Drew, J; Glaser, DA; Green, L; Hebert, AA; Mamelok, RD; Nast, A; Pariser, DM; Quiring, J; Werschler, WP, 2019)	0.51
" Adverse events were also assessed."	( Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. DeAngelis, K; Dorinsky, P; Ferguson, GT; Kerwin, EM; Mo, M, 2019)	0.79
" The incidence of treatment-emergent adverse events (TEAEs) was generally similar among groups."	( Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. DeAngelis, K; Dorinsky, P; Ferguson, GT; Kerwin, EM; Mo, M, 2019)	0.79
" All the treatment-emergent adverse events (TEAEs) were mild and no severe TEAE was reported."	( Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Hu, C; Luo, Z; Miao, J; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" BDP/FF/GB pMDI was safe and well tolerated in healthy Chinese subjects."	( Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Hu, C; Luo, Z; Miao, J; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" Safety was evaluated over 52 weeks via adverse event (AE) monitoring, electrocardiograms, clinical laboratory testing, and vital sign measurements."	( Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. Aurivillius, M; Ballal, S; Bourne, E; DeAngelis, K; Dorinsky, P; Ferguson, GT; Fukushima, Y; Hataji, O; Hayashi, N; Ichinose, M; Inoue, Y; Okada, H; Rabe, KF; Reisner, C; Takikawa, M, 2019)	0.78
" Most treatment-related adverse events were mild or moderate."	( Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial. Baumann, L; Bhatia, N; Chadha, D; Cohen, J; DuBois, J; Green, L; Kirsch, B; Liu, PY; Pariser, D; Smith, S; Walker, P, 2020)	0.56
" Safety assessments included treatment-emergent adverse events (TEAEs) and local skin reactions (LSRs)."	( Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study. Cather, J; Drew, J; Glaser, DA; Gopalan, R; Green, L; Hebert, AA; Hull, C; Pariser, DM, 2020)	0.56
" Treatment was safe: most treatment-emergent adverse effects were mild or moderate, and transient."	( A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Abels, C; Heimstaedt-Muskett, S; Jourdan, C; Kilic, A; Knie, U; Masur, C; Reich, H; Schramm, K; Soeberdt, M; Szeimies, RM, 2021)	0.62
" Being familiar with new medications and their side effect profiles can prevent unnecessary or harmful interventions."	( A new medication, a new toxidrome - A case report of anticholinergic wipe toxicity due to improper medication use. Michael, T; Paul, C, 2021)	0.62
" Specifically, this study assessed the impact of sugammadex on cardiac adverse events (AEs) and other prespecified AEs of clinical interest."	( A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants. Blobner, M; Broussard, DM; Herring, WJ; Lin, L; Lombard, JF; Lutkiewicz, J; Mukai, Y; Wang, A; Watkins, M, 2021)	0.62
"Pediatric sedation is a clinical activity with potential for serious but rare airway adverse events, particularly laryngospasm."	( Anticholinergics and serious adverse events in pediatric procedural sedation: A report of the pediatric sedation research consortiums. Boriosi, JP; Ferrazzano, P; Hollman, GA; Lasarev, MR; Peters, ME, 2022)	0.72
"The objective of this study is to describe the current practice of anticholinergic use in pediatric sedation and to compare the frequency of serious sedation-related adverse events in patients who received anticholinergics to those who did not."	( Anticholinergics and serious adverse events in pediatric procedural sedation: A report of the pediatric sedation research consortiums. Boriosi, JP; Ferrazzano, P; Hollman, GA; Lasarev, MR; Peters, ME, 2022)	0.72
" Patient characteristics, procedure type, sedation provider, sedatives, location of sedation, anticholinergic administered, adverse events, and airway interventions were reported."	( Anticholinergics and serious adverse events in pediatric procedural sedation: A report of the pediatric sedation research consortiums. Boriosi, JP; Ferrazzano, P; Hollman, GA; Lasarev, MR; Peters, ME, 2022)	0.72
" Use of anticholinergics was more common in patients with well-described risk factors for airway adverse events: active/history of upper respiratory infection, history of reactive airway disease/asthma, and exposure to smoke."	( Anticholinergics and serious adverse events in pediatric procedural sedation: A report of the pediatric sedation research consortiums. Boriosi, JP; Ferrazzano, P; Hollman, GA; Lasarev, MR; Peters, ME, 2022)	0.72
"In this large Pediatric Sedation Research Consortium study, we found the use of anticholinergic adjuvants independently associated with greater odds of serious adverse events, especially airway adverse events, after adjusting for well-known sedation risk factors using propensity score matching and multivariate analysis."	( Anticholinergics and serious adverse events in pediatric procedural sedation: A report of the pediatric sedation research consortiums. Boriosi, JP; Ferrazzano, P; Hollman, GA; Lasarev, MR; Peters, ME, 2022)	0.72
" The primary endpoint was incidence and severity of treatment-emergent adverse events (AEs) over 52-weeks."	( Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week st D'Andrea, P; Hosoe, M; Matsuo, K; Nakamura, Y; Pethe, A; Sagara, H; Tanaka, Y; Tanase, AM, 2023)	0.91
" Safety data, including local skin reactions and other adverse events, were tabulated by cohort."	( Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis. Benedict, D; Pariser, D; Rivera, E, 2022)	0.72
" The most common adverse event was unilateral mydriasis, which presumably occurred from inadvertent introduction of study drug into the eye despite multiple warnings to the subjects to avoid eye contact."	( Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis. Benedict, D; Pariser, D; Rivera, E, 2022)	0.72
" Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects."	( Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate. Chang, HC; Lee, MJ; Lee, SO; Liu, SY; Wong, CS, 2022)	0.93
" Treatment was safe and locally well-tolerated with only few mild to moderate adverse drug reactions (ADRs)."	( Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial. Abels, C; Berger, B; Heimstaedt-Muskett, S; Kilic, A; Litzka, L; Masur, C; Reich, H; Schramm, K; Schulze Zur Wiesche, E; Szeimies, RM, 2023)	0.91

Excerpt	Reference	Relevance
"97) micrograms/l and mean Tmax (time to Cmax) of 13."	( Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J, 1990)	0.53
"1 min and mean elimination half-life of 75."	( Pharmacokinetics of i.m. glycopyrronium. Ali-Melkkilä, TM; Iisalo, E; Kaila, T; Kanto, J, 1990)	0.28
"5) ng/ml, a mean time to Cmax (Tmax) of 10."	( Pharmacokinetics of glycopyrronium in parturients. Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J, 1990)	0.28
"In the present study, a sensitive and reproducible radioreceptor assay (RRA) was used to evaluate the basic pharmacokinetic properties of glycopyrrolate, a quaternary amine with peripheral antimuscarinic activity."	( Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Ali-Melkkilä, T; Kaila, T; Kanto, J, 1989)	1.92
"Several specific and sensitive new methods for determining atropine and its metabolites in biological fluids have increased the possibility to characterise the pharmacokinetic properties of this antimuscarinic agent."	( Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Kanto, J; Klotz, U, 1988)	0.5
" The only significant difference in the pharmacokinetic parameters was the shortened elimination half-life in patients between 1 and 3 years of age."	( Pharmacokinetics of glycopyrrolate in children. Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P, )	0.45
" The shortened elimination half-life in children between 1 and 3 years of age is of minor clinical importance."	( Pharmacokinetics of glycopyrrolate in children. Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P, )	0.45
"The pharmacokinetics and some pharmacodynamic properties of atropine, glycopyrrolate and scopolamine are reviewed."	( Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Ali-Melkkilä, T; Iisalo, E; Kanto, J, 1993)	0.52
" In this study, we used population pharmacokinetic (PK) modelling to provide insights into the impact of the lung PK of glycopyrronium on its systemic PK profile and, in turn, to understand the impact of lung bioavailability and residence time on the choice of dosage regimen."	( Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Bartels, C; Kaiser, G; Looby, M; Sechaud, R, 2013)	0.39
" Its extended intrapulmonary residence time also provides pharmacokinetic evidence that glycopyrronium has the profile of a once-daily drug."	( Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Bartels, C; Kaiser, G; Looby, M; Sechaud, R, 2013)	0.39
" Although GLY is used routinely in veterinary patients, there is limited information regarding its pharmacokinetic (PK) and pharmacodynamic (PD) properties in domestic animals, and an improved understanding of the plasma concentration-effect relationship in racehorses is warranted."	( Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse. Hochhaus, G; Kandala, B; Rumpler, MJ; Sams, RA; Vickroy, TW, 2014)	0.67
" The primary pharmacokinetics (PK) parameters were plasma peak concentration (Cmax), AUC up to the last measured concentration (AUClast), and renal clearance (CLr) of glycopyrronium."	( Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Camenisch, G; Drollmann, A; Dumitras, S; Kaiser, G; Pal, P; Sechaud, R; Vaidyanathan, S, 2013)	0.39
" Cmax was not affected."	( Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Camenisch, G; Drollmann, A; Dumitras, S; Kaiser, G; Pal, P; Sechaud, R; Vaidyanathan, S, 2013)	0.39
"The disposition of plasma glycopyrrolate (GLY) is characterized by a three-compartment pharmacokinetic model after a 1-mg bolus intravenous dose to Standardbred horses."	( The pharmacokinetics of glycopyrrolate in Standardbred horses. Colahan, P; Rumpler, MJ; Sams, RA, 2014)	1.01
" A population pharmacokinetic (PK) analysis was performed to describe the PK profiles of indacaterol and glycopyrronium following the twice daily (b."	( Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients. Bartels, C; Bieth, B; Demin, I; Gautier, A; Graham, G; Sechaud, R; Tillmann, HC, 2016)	0.43
"This was a Phase I, randomized, double-blind, placebo-controlled, ascending-dose, crossover study to assess the safety and pharmacokinetic profiles of two doses of BGF MDI in healthy adult subjects of Japanese descent (NCT02197975)."	( Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. DePetrillo, P; Dorinsky, P; Maes, A; Reisner, C; Siddiqui, S, 2018)	0.48
"Twenty subjects were randomized and included in the safety and pharmacokinetic populations; mean age 29."	( Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. DePetrillo, P; Dorinsky, P; Maes, A; Reisner, C; Siddiqui, S, 2018)	0.48
"This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28."	( Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. DePetrillo, P; Maes, A; Martin, UJ; Miller, J; Reisner, C; Siddiqui, S, 2018)	0.48
"We conducted two studies to characterize the pharmacokinetic (PK) profile of BGF MDI in patients with COPD: (i) a phase I, open-label, single and chronic (7-day) dosing study (NCT03250182) with one treatment arm (BGF MDI 320/18/9."	( Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Darken, P; DeAngelis, K; Dorinsky, P; Dunn, LJ; Gillen, M; Kerwin, EM, 2020)	0.84
" Limited data on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of BDP/FF/GB fixed-dose combination in healthy subjects was available."	( Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Hu, C; Luo, Z; Miao, J; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" Heart rate (HR), QTcF, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated as the surrogate indicators of pharmacodynamic effects."	( Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Hu, C; Luo, Z; Miao, J; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" The dose adjusted pharmacokinetic profiles of BDP, beclomethasone-17-monopropionate (B17MP, the most active metabolite of BDP), formoterol and GB were overall similar in therapeutic and supra- therapeutic dose group, showing dose proportional increase of the systemic exposure to BDP, B17MP, formoterol and GB."	( Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Hu, C; Luo, Z; Miao, J; Shu, S; Wang, Y; Zhu, X, 2020)	0.56
" A physiologically based pharmacokinetic (PBPK) model was developed in patients with COPD with normal renal function and used to predict systemic exposure of glycopyrronium in patients with severe renal impairment."	( Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment. Gillen, M; Higashimori, M; Ishikawa, K; Zhou, D, 2021)	0.62
" There was no clinically relevant pharmacokinetic interaction between IND, GLY and MF when administered as IND/GLY/MF."	( Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Abdallah, N; Drollmann, A; Ethell, B; Hahn, M; Heudi, O; Ignatenko, S; Jauernig, J; Last, S; Machineni, S; Radhakrishnan, R; Tillmann, HC; Vaidya, S, 2020)	0.56
" However, pharmacokinetic (PK) studies of other drugs have shown that ethnic factors (e."	( Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Assam, PN; Dorinsky, P; Feng, C; Gillen, M; Huang, Y; Su, R, 2020)	0.81
"Clinical evidence suggests no clinically relevant pharmacokinetic interactions between indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF)."	( Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J, 2021)	0.62
"The final pharmacokinetic models were two-compartment disposition models with first-order elimination and sequential zero-order/first-order absorption (IND), with bolus administration and first-order elimination (GLY), and with mixed zero-order/first-order absorption and first-order elimination (MF)."	( Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J, 2021)	0.62
" The pharmacokinetic profiles of MF were comparable for combination products at corresponding medium- or high-dose inhaled corticosteroids."	( Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J, 2021)	0.62

Excerpt	Reference	Relevance
" It is suggested that glycopyrrolate should be used in combination with antacid therapy before obstetric anaesthesia and puerperal tubal ligation because of its prolonged duration of action, effect on gastric secretion and failure to cross the placental barrier."	( Effects of glycopyrrolate and atropine combined with antacid on gastric acidity. Roper, RE; Salem, MG, 1981)	0.97
"No more effective than tiotropium combined with formoterol."	( Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD. , 2014)	0.4
" The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.42
"This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50 µg, once-daily tiotropium (TIO) 18 µg or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.42
"Seventy-four patients undergoing TURBT were randomly allocated to receive either glycopyrrolate 10 μg/kg (glycopyrrolate group, n = 37) or atropine 15 μg/kg (atropine group, n = 37) in combination with neostigmine 25 μg/kg at the end of surgery for reversal of neuromuscular blockade."	( Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study. Kim, HC; Lim, SM; Park, HP; Seo, H, 2015)	1.05
"This two-period, open-label, crossover study examined the drug-drug interaction of CHF 5993 and cimetidine."	( A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. Acerbi, D; Ciurlia, G; Mariotti, F; Muraro, A; Spaccapelo, L, 2017)	0.46
"Overall, this study indicates that there is no clinically relevant drug-drug interaction between CHF 5993 and cimetidine."	( A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. Acerbi, D; Ciurlia, G; Mariotti, F; Muraro, A; Spaccapelo, L, 2017)	0.46
" PROCEDURES In a randomized crossover study, each dog received 5 premedication protocols (medetomidine [10 μg/kg, IV] alone [MED] and in combination with MK-467 at doses of 50 [MMK50], 100 [MMK100], and 150 [MMK150] μg/kg and 15 minutes after glycopyrrolate [10 μg/kg, SC; MGP]), with at least 14 days between treatments."	( Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane. Bennett, RC; Kuusela, E; Raekallio, MR; Salla, KM; Scheinin, M; Tuns, CI; Vainio, OM, 2017)	0.85
"A simple and sensitive analytical method for four isomers of glycopyrrolate in rat plasma was developed using cation-selective exhaustive injection-sweeping cyclodextrin-modified electrokinetic chromatography (CSEI-Sweeping-CDEKC) for online enrichment combined with dispersive micro-solid-phase extraction pretreatment."	( Dispersive micro-solid-phase extraction combined with online preconcentration by capillary electrophoresis for the determination of glycopyrrolate stereoisomers in rat plasma. Chen, D; Liu, Y; Yu, L; Zhang, H, 2018)	0.93

Excerpt	Reference	Relevance
" or oral atropine administration, typical anticholinergic effects coincide quite well with the absorption rate of the drug, indicating that the premedication should be given about 1 and 2 h before induction of anaesthesia."	( Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Kanto, J; Klotz, U, 1988)	0.5
" Glycopyrrolate is a quaternary ammonium anticholinergic compound that is poorly absorbed from mucus membranes, thus reducing anticholinergic side effects."	( Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. Bush, RK; Busse, WW; Chervinsky, P; Schroeckenstein, DC, 1988)	1.4
" Because of the quaternary nature, it is poorly absorbed when taken orally and penetrates neither placental nor blood-brain barriers."	( [Glycopyrrolate (Robinul), a new anticholinergic substance]. Cozanitis, DA; Krieg, N, 1983)	1.18
"Based on plasma levels determined with a radioreceptor assay and following a single oral (50 micrograms/kg) and intravenous (5 micrograms/kg) administration of glycopyrrolate in six healthy children operated twice during a several weeks period, a negligible and variable oral bioavailability was found (3."	( Pharmacokinetics and oral bioavailability of glycopyrrolate in children. Ali-Melkkilä, T; Kaila, T; Kanto, J; Manner, T; Olkkola, K; Rautakorpi, P, 1998)	0.76
" In this study, we used population pharmacokinetic (PK) modelling to provide insights into the impact of the lung PK of glycopyrronium on its systemic PK profile and, in turn, to understand the impact of lung bioavailability and residence time on the choice of dosage regimen."	( Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Bartels, C; Kaiser, G; Looby, M; Sechaud, R, 2013)	0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" genetic factors affecting drug metabolism) can affect the bioavailability of drugs which may impact upon efficacy and safety outcomes."	( Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Assam, PN; Dorinsky, P; Feng, C; Gillen, M; Huang, Y; Su, R, 2020)	0.81

Excerpt	Relevance	Reference
" The latter dosage of this drug combination thus appears preferable in patients presenting for emergency surgery, if the integrity of the lower oesophageal sphincter is to be maintained during extubation and recovery from general anaesthesia."	( Reversal of neuromuscular blockade by glycopyrrolate and neostigmine. A study of the effects on lower oesophageal sphincter tone. Brock-Utne, JG, )	0.4
" Furthermore, significant bronchodilation was noted within 30 minutes of dosing and was sustained for at least 12 hours."	( Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. Bush, RK; Busse, WW; Chervinsky, P; Schroeckenstein, DC, 1988)	0.49
" It was concluded that glycopyrrolate enhanced atracurium-induced neuromuscular blockade in the rat diaphragm preparation, and that this effect should be noted when dosing glycopyrrolate in man."	( Glycopyrrolate intensifies neuromuscular blockade produced by atracurium in the rat diaphragm preparation. Altinel, A; Dark, CH; Jones, CJ; Wali, FA, 1987)	2.03
" After administration of glycopyrrolate, cardiac performance decreased, but the decrease was not significant when compared with the ventricular performance of the cats after administration of the large dosage of xylazine."	( Cardiac performance in cats after administration of xylazine or xylazine and glycopyrrolate: echocardiographic evaluations. Dunkle, N; Moise, NS; Scarlett-Kranz, J; Short, CE, 1986)	0.8
" It is suggested that the dosage of anticholinergic agents given with neostigmine could be reduced in elderly patients in comparison to that in younger patients."	( Antagonism of neuromuscular block in the elderly. A comparison of atropine and glycopyrronium in a mixture with neostigmine. Mirakhur, RK, 1985)	0.27
" After several pilot dose-response studies, we administered 8 mg of the cholinergic agonist arecoline subcutaneously to eight pairs of normal volunteer identical twins and eight bipolar patients currently euthymic and unmedicated."	( Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients. Gershon, ES; Gillin, JC; Jimerson, DC; Lawrence, D; Nadi, NS; Nurnberger, JI; Simmons-Alling, S; Sitaram, N; Tamminga, C, 1983)	0.27
" Glycopyrrolate, being about twice as potent as atropine in the clinical situation, was used in half the dosage of atropine."	( A comparison of atropine and glycopyrrolate in anaesthetic practice. Kongsrud, F; Sponheim, S, 1982)	1.47
" Glycopyrrolate was administered IV and IM at a dosage of 11 micrograms/kg of body weight, each."	( Alterations in the arrhythmogenic dose of epinephrine after xylazine or medetomidine administration in halothane-anesthetized dogs. Benson, GJ; Lemke, KA; Olson, WA; Thurmon, JC; Tranquilli, WJ, 1993)	1.2
" Glycopyrrolate was administered IV and IM at a dosage of 11 micrograms/kg of body weight, each."	( Alterations in the arrhythmogenic dose of epinephrine after xylazine or medetomidine administration in isoflurane-anesthetized dogs. Benson, GJ; Lemke, KA; Olson, WA; Thurmon, JC; Tranquilli, WJ, 1993)	1.2
" One alternative is the combination of glycopyrrolate, alfentanil and suxamethonium described here, although the ideal medication and dosage still remain to be defined."	( Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates. Koivisto, M; Pokela, ML, 1994)	0.56
"Prospective, open-label study of drug dosage parameters, response to therapy, and side effects."	( Glycopyrrolate treatment of chronic drooling. Blasco, PA; Stansbury, JC, 1996)	1.74
"001), whereas glycopyrrolate increased peak HR to sea level values, 184 +/- 3 beats/min, confirming adequate dosing with each drug."	( Role of the autonomic nervous system in the reduced maximal cardiac output at altitude. Bogaard, HJ; Hopkins, SR; Niizeki, K; Wagner, PD; Yamaya, Y; Ziegler, MG, 2002)	0.68
" The urine method described in this report is simple and efficient and is the first reported method with sufficient sensitivity, accuracy, and precision to regulate the use of glycopyrrolate in urine samples collected more than one day after dosing of horses."	( Regulatory control of glycopyrrolate in performance horses using validated UHPLC/MS-MS methods. Colahan, P; Rumpler, MJ; Sams, RA, 2012)	0.89
" At a mean dosage of 2 mg daily, 90% of patients experienced improvement, which was major in 71% of responders."	( Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. Chamlin, SL; Mancini, AJ; Paller, AS; Shah, PR; Silverio, AM; Wagner, A, 2012)	0.89
" All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12."	( A novel model-based approach for dose determination of glycopyrronium bromide in COPD. Alagappan, V; Arievich, H; Banerji, D; Gibbs, M; Looby, M; Overend, T; Renard, D, 2012)	0.38
" Importantly, OD dosing may confer better patient adherence."	( A novel model-based approach for dose determination of glycopyrronium bromide in COPD. Alagappan, V; Arievich, H; Banerji, D; Gibbs, M; Looby, M; Overend, T; Renard, D, 2012)	0.38
" In this study, we used population pharmacokinetic (PK) modelling to provide insights into the impact of the lung PK of glycopyrronium on its systemic PK profile and, in turn, to understand the impact of lung bioavailability and residence time on the choice of dosage regimen."	( Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Bartels, C; Kaiser, G; Looby, M; Sechaud, R, 2013)	0.39
" The estimated 24-hour potency (expressed as concentration of dosing solution) was 45."	( In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. Hegde, SS; Jaw-Tsai, S; Ji, Y; Martin, WJ; McNamara, A; Obedencio, GP; Pulido-Rios, MT, 2013)	0.39
" Oral glycopyrrolate is emerging as a potential second-line treatment option, but experience with safety, efficacy, and dosing is especially limited in children."	( Oral glycopyrrolate for refractory pediatric and adolescent hyperhidrosis. Bayliss, SJ; Berk, DR; Foreman, RS; Kumar, MG, )	1.13
" When dual bronchodilation is indicated, QVA149 offers the convenience of two bronchodilators in a single inhaler coupled with a simple, once-daily dosing regimen that may encourage better treatment adherence."	( QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Frampton, JE, 2014)	0.4
" In addition, these findings indicate that the correct dosage of glycopyrronium is no more than 115."	( Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. Darken, P; Fernandez, C; Fischer, T; Fogarty, C; Golden, M; Orevillo, C; Reisner, C; Rennard, S; Rose, ES; Tardie, G, 2014)	0.4
"To establish the dose-response for pharmacodynamics (bronchodilatation), safety and pharmacokinetics for a nebulized formulation of the long acting muscarinic antagonist glycopyrrolate (EP-101) with a high efficiency nebulizer in patients with chronic obstructive pulmonary disease (COPD)."	( Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Barnes, PJ; Jones, CR; Leaker, BR; Singh, D; Tutuncu, A, 2015)	0.89
" Significant improvements in mean change from baseline FEV1 at 24 h were reported at doses ≥ 50 μg compared with placebo, with a clear dose-response relationship."	( Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Barnes, PJ; Jones, CR; Leaker, BR; Singh, D; Tutuncu, A, 2015)	0.7
"Adult patients undergoing abdominal surgery received rocuronium, followed by randomized allocation to sugammadex (2 or 4 mg kg(-1)) or usual care (neostigmine/glycopyrrolate, dosing per usual care practice) for reversal of neuromuscular blockade."	( Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Brueckmann, B; de Bie, J; Eikermann, M; Grobara, P; Kwo, J; Lee, J; Li, MK; Maktabi, M; McGovern, F; Pino, R; Sabouri, AS; Sasaki, N; Staehr-Rye, AK; Woo, T, 2015)	0.61
" Virtual clinical trials were simulated and analyzed using conventional (at the end of the study) versus model-based methods to determine sample size for achieving 80% power to identify a dose-response relationship."	( Pharmacometrics-guided drug development of antihyperhidrosis agents. Dumitrescu, TP; Gobburu, J; Mehrotra, S; Schmith, VD, 2015)	0.42
" Anaesthetized Brown Norway rats were dosed intratracheally at 1 or 6h prior to receiving increasing doses of intravenous methacholine."	( Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Charlton, SJ; Collingwood, S; Ethell, BT; Kent, TC; Sykes, DA; Trifilieff, A; Watson, KJ, 2015)	0.42
"Three spectrophotometric methods have been developed and validated for determination of indacaterol (IND) and glycopyrronium (GLY) in their binary mixtures and novel pharmaceutical dosage form."	( Simultaneous spectrophotometric determination of indacaterol and glycopyrronium in a newly approved pharmaceutical formulation using different signal processing techniques of ratio spectra. Abdel Ghany, MF; Hussein, LA; Magdy, N; Yamani, HZ, 2016)	0.43
"To establish the dose-response relationship for pharmacodynamics (bronchodilatation), safety and pharmacokinetics of a novel particle engineered formulation of Glycopyrronium bromide (PSX1002-GB) in patients with chronic obstructive pulmonary disease (COPD)."	( Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study. Buck, H; Down, G; O'Connor, G; Ravi, A; Reid, F; Singh, D, 2016)	0.43
"This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to determine the dose-response of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB) when added to beclometasone dipropionate plus formoterol fumarate (BDP/FF) in patients with COPD."	( The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). Bonnet-Gonod, F; Cohuet, G; Hoffmann, M; Muraro, A; Petruzzelli, S; Schröder-Babo, W; Siergiejko, Z; Singh, D, 2016)	0.43
"The lack of commercially available liquid dosage forms for pediatric patients prompted this study."	( Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures. Nahata, MC, )	0.38
" In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD."	( Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). Aalamian-Mattheis, M; Beeh, KM; Casamor, R; Castellani, W; Clemens, A; Gunstone, A; Kostikas, K; Marin, JM; Saralaya, D; Schaper, L, 2016)	0.43
"This study forms part of the first complete characterization of the dose-response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI)."	( Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Darken, P; Dwivedi, S; Fabbri, LM; Ferguson, GT; Fischer, T; Golden, M; Kerwin, EM; Orevillo, C; Pearle, J; Reisner, C; Rodriguez-Roisin, R; Sethi, S; Spangenthal, S; St Rose, E, 2016)	0.96
" Here we review multiple studies from 1972 through 1986 that used varying methods of patient selection and dosage and drug combination criteria, and which noted that glycopyrrolate had a superior efficacy and adverse effect profile when compared with atropine in NMB reversal."	( Glycopyrrolate: It's time to review. D'mello, J; Howard, J; Rosen, G; Wigley, J, 2017)	2.09
"Methacholine dose-response curves illustrate pharmacologic bronchoprotection against methacholine-induced airway hyperresponsiveness and can be used to quantitate changes in airway sensitivity (position), reactivity (slope), and maximal responsiveness following drug administration."	( The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Blais, CM; Cockcroft, DW; Davis, BE, 2017)	0.46
"Methacholine dose-response curves differentiate the bronchoprotective mechanisms triggered by different classes of asthma medications."	( The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Blais, CM; Cockcroft, DW; Davis, BE, 2017)	0.46
"GFF MDI significantly improved 24-h lung function versus placebo in patients with moderate-to-very severe chronic obstructive pulmonary disease, with similar benefits in the second 12-h period compared to the first, supporting twice-daily dosing of GFF MDI."	( 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Arora, S; Delacruz, L; Fakih, F; Feldman, G; Gottschlich, G; Koser, A; Krainson, J; Maes, A; Martin, U; Orevillo, C; Pudi, K; Reisner, C; Siddiqui, S; St Rose, E, 2017)	0.69
" The plasma concentration-time profiles of glycopyrronium were similar following treatment with GFF MDI or GP MDI, both after single dosing and at Week 12."	( Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Ferguson, GT; Maes, A; Martin, UJ; Reisner, C; Rodriguez-Roisin, R; Siddiqui, S, 2018)	0.48
" Pharmacokinetic parameters were assessed following a single dose and 7-days chronic dosing with BGF MDI 160/14."	( Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. DePetrillo, P; Dorinsky, P; Maes, A; Reisner, C; Siddiqui, S, 2018)	0.48
"6 µg nor a clear dose-response was observed."	( Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. Darken, P; Kerwin, EM; Pearle, J; Reisner, C; Rose, ES, 2018)	0.75
"We conducted two studies to characterize the pharmacokinetic (PK) profile of BGF MDI in patients with COPD: (i) a phase I, open-label, single and chronic (7-day) dosing study (NCT03250182) with one treatment arm (BGF MDI 320/18/9."	( Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Darken, P; DeAngelis, K; Dorinsky, P; Dunn, LJ; Gillen, M; Kerwin, EM, 2020)	0.84
"Steady-state PK parameters of budesonide, glycopyrronium, and formoterol were similar after 7 days' dosing in the phase I PK study and after 24 weeks in the KRONOS PK sub-study."	( Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Darken, P; DeAngelis, K; Dorinsky, P; Dunn, LJ; Gillen, M; Kerwin, EM, 2020)	0.84
" Postdose efficacy assessments were performed within 60-150 min of dosing on day 15."	( Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. De Backer, J; De Backer, W; Fitzpatrick, J; Griffis, D; Ivanov, S; Jenkins, M; Leemans, G; Martin, UJ; Mignot, B; Reisner, C; St Rose, E; Van Holsbeke, C; Verlinden, I, )	0.39
" The observed differences may be caused by the difference in dosing between the two regimens."	( Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Carpaij, OA; Kerstjens, HAM; Niemeijer, A; Seigers, D; van Geffen, WH; Vonk, JM; Westbroek, LF, 2020)	0.56
" Overall, PK properties following single or repeated dosing of BGF MDI were similar across Chinese, Japanese and Western subjects."	( Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Assam, PN; Dorinsky, P; Feng, C; Gillen, M; Huang, Y; Su, R, 2020)	0.81
" Patients were treated with 1% GPB cream once daily for 4 weeks, followed by a flexible dosing scheme (min."	( Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial. Abels, C; Berger, B; Heimstaedt-Muskett, S; Kilic, A; Litzka, L; Masur, C; Reich, H; Schramm, K; Schulze Zur Wiesche, E; Szeimies, RM, 2023)	0.91

Class	Description
quaternary ammonium salt	Derivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
organic bromide salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	2.9799	0.0002	29.3054	16,493.5996	AID743069; AID743080
cytochrome P450 2D6	Homo sapiens (human)	Potency	15.4871	0.0010	8.3798	61.1304	AID1645840
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	100.0000	0.3548	28.0659	89.1251	AID504847
Cellular tumor antigen p53	Homo sapiens (human)	Potency	7.4978	0.0023	19.5956	74.0614	AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0000	1.2326	7.7930	AID539981
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.0016	0.0000	0.6902	10.0000	AID1591564
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0000	1.1546	7.5858	AID539982
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0001	0.9917	8.0000	AID539983
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0000	1.4039	10.0000	AID539980
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0001	1.0104	9.9280	AID539979
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	0.0008	0.0000	0.5405	7.7600	AID1591563
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1224077	Effect on CCh-induced salivation in Sprague-Dawley rat after 24 hrs	2014	Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13	Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1224075	Bronchodilatory effect in it dosed Sprague-Dawley rat assessed as inhibition of CCh-induced bronchoconstriction after 24 hrs	2014	Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13	Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID771315	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID539983	Displacement of [3H]NMS from human muscarinic M5 receptor expressed in CHO-K1 cells after 16 hrs by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	The discovery of new spirocyclic muscarinic M3 antagonists.
AID1591568	Bronchodilatory activity in tracheotomized ICR mouse assessed as suppression of methacholine-induced increase in airway resistance at 3.6 ug/kg administered intratracheally 1 hr before by methacholine challenge	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID1591564	Displacement of [3H]NMS from human M2R expressed in CHOK1 cell membranes incubated for 2 hrs by microbeta scintillation counting method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID771314	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1591577	Bronchodilatory activity in tracheotomized ICR mouse at 3.6 ug/kg administered intratracheally measured after 96 hrs	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1591575	Bronchodilatory activity in tracheotomized ICR mouse at 3.6 ug/kg administered intratracheally measured after 72 hrs	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID539981	Displacement of [3H]NMS from human muscarinic M2 receptor expressed in CHO-K1 cells after 16 hrs by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	The discovery of new spirocyclic muscarinic M3 antagonists.
AID771317	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID771316	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1591572	Bronchodilatory activity in tracheotomized ICR mouse at 3.6 ug/kg administered intratracheally measured after 48 hrs	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1224076	Ratio of ID50 for effect on CCh-induced salivation in Sprague-Dawley rat to ID50 for inhibition of CCh-induced bronchoconstriction Sprague-Dawley rat	2014	Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13	Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists.
AID539979	Displacement of [3H]NMS from human muscarinic M3 receptor expressed in CHO-K1 cells after 16 hrs by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	The discovery of new spirocyclic muscarinic M3 antagonists.
AID539982	Displacement of [3H]NMS from human muscarinic M4 receptor expressed in CHO-K1 cells after 16 hrs by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	The discovery of new spirocyclic muscarinic M3 antagonists.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1224081	Bronchodilatory effect in it dosed Sprague-Dawley rat assessed as inhibition of CCh-induced bronchoconstriction at 15 mins to 1 hr	2014	Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13	Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists.
AID539980	Displacement of [3H]NMS from human muscarinic M1 receptor expressed in CHO-K1 cells after 16 hrs by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	The discovery of new spirocyclic muscarinic M3 antagonists.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1591563	Displacement of [3H]NMS from human M3R expressed in CHOK1 cell membranes incubated for 2 hrs by microbeta scintillation counting method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	268 (24.17)	18.7374
1990's	154 (13.89)	18.2507
2000's	141 (12.71)	29.6817
2010's	381 (34.36)	24.3611
2020's	165 (14.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	404 (33.72%)	5.53%
Reviews	121 (10.10%)	6.00%
Case Studies	135 (11.27%)	4.05%
Observational	10 (0.83%)	0.25%
Other	528 (44.07%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (186)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [NCT00510510]	Phase 2	281 participants (Actual)	Interventional	2007-08-31	Completed
Evaluation of the Anti-inflammatory Effects of Glycopyrronium Added to Indacaterol/Mometasone on the Allergen-induced Late Asthmatic Response [NCT04259164]	Phase 3	28 participants (Actual)	Interventional	2020-09-10	Completed
The Effect of Sugammadex of EEG-derived Index Values [NCT01142648]	Phase 4	30 participants (Anticipated)	Interventional	2009-04-30	Completed
A Randomized, Double-Blind, Chronic Dosing (7-Day), Four-Period, Four-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD [NCT03256552]	Phase 2	66 participants (Actual)	Interventional	2015-01-28	Completed
A Prospective, Double-blind, Randomized Study to Investigate the Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Emergence Delirium During Sevoflurane-rocuronium Anesthesia in Pediatric Patients [NCT03229486]	Phase 4	40 participants (Actual)	Interventional	2017-03-01	Completed
Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers. [NCT01176851]	Phase 1	20 participants (Anticipated)	Interventional	2010-07-31	Completed
A Phase I, Randomised, Two-Period, Single-Dose, Single-Centre, Crossover Gamma Scintigraphy Study to Assess the Pulmonary Deposition of Technetium-99m Radiolabelled Budesonide, Glycopyrronium and Formoterol Fumarate MDI, Following 3 s and 10 s Breath-Hold [NCT03740373]	Phase 1	10 participants (Actual)	Interventional	2018-09-04	Completed
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants [NCT03351608]	Phase 4	288 participants (Actual)	Interventional	2018-02-12	Completed
A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects [NCT03346070]	Phase 4	207 participants (Actual)	Interventional	2018-01-01	Completed
Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single-Dose, 6-Way Crossover Study to Assess Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebuliser in Patients With COPD [NCT02948582]	Phase 2	42 participants (Actual)	Interventional	2010-07-31	Completed
Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients. [NCT01176903]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (A [NCT03346057]	Phase 4	344 participants (Actual)	Interventional	2017-12-20	Completed
A Novel Application of Iontophoresis in the Transcutaneous Delivery of a Prokinetic Agent for the Promotion of Bowel Evacuation [NCT02370862]	Early Phase 1	28 participants (Actual)	Interventional	2013-02-28	Completed
A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients [NCT03162055]	Phase 3	1,119 participants (Actual)	Interventional	2017-05-25	Completed
A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for [NCT03075267]	Phase 1	96 participants (Actual)	Interventional	2017-04-17	Completed
Open Label, Prospective Study to Evaluate the Effect of Step-up From Non-extra Fine Inhaled Corticosteroids/Long Acting Beta2 Agonist (ICS/LABA) Dry Powder Inhaler (DPI) to Extra Fine Triple Therapy With CHF5993 DPI on Airway Geometry and Lung Ventilation [NCT04876677]	Phase 3	25 participants (Actual)	Interventional	2021-05-25	Completed
Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer [NCT02119234]	Phase 1	36 participants (Actual)	Interventional	2014-03-31	Completed
A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures [NCT03138967]	Phase 4	54 participants (Actual)	Interventional	2017-09-18	Completed
A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF CHF 5259 (GLYCOPYRROLATE) PLUS FOSTER® 100/6 µg (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE PL [NCT02127866]	Phase 2	211 participants (Actual)	Interventional	2014-04-30	Completed
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative [NCT02867761]	Phase 3	780 participants (Actual)	Interventional	2017-08-29	Completed
Glycopyrrolate Prophylaxis for Prevention of Bradyarrhythmia During Laparoscopic Cholecystectomy [NCT05997004]		62 participants (Actual)	Interventional	2018-05-01	Completed
A Phase II, Randomized, Double Blind, Double Dummy, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [NCT06035393]	Phase 2	200 participants (Anticipated)	Interventional	2023-10-27	Not yet recruiting
Effectiveness of Sugammadex Versus Neostigmine on Neuromuscular Reversal in Pediatric Patients Undergoing Laparoscopic Appendectomy for Acute Appendicitis: A Randomized Controlled Trial [NCT05256901]	Phase 4	120 participants (Anticipated)	Interventional	2023-07-19	Recruiting
A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmon [NCT02189577]	Phase 2	100 participants (Actual)	Interventional	2014-06-30	Completed
Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging [NCT03268226]	Phase 3	20 participants (Actual)	Interventional	2017-11-20	Completed
Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine [NCT02430272]		84 participants (Actual)	Interventional	2014-05-31	Completed
The Use of Propofol/Ketamine Anesthesia With Bispectral Monitoring (PKA-BIS) Versus Inhalational Anesthetics in Rhytidoplasty - A Prospective, Double-blinded, Randomized Comparison Study [NCT02410460]		30 participants (Actual)	Interventional	2013-09-30	Completed
Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic Polypectomy: a Randomized, Double-blind, Placebo-controlled Study [NCT06041984]	Phase 1/Phase 2	150 participants (Anticipated)	Interventional	2023-10-08	Enrolling by invitation
Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine [NCT02825576]	Phase 4	30 participants (Actual)	Interventional	2018-12-03	Terminated(stopped due to Lack of Study Personnel)
Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the T [NCT05948891]		500 participants (Anticipated)	Observational	2023-07-31	Not yet recruiting
A Phase IV, Open Label, Multicentre, Randomised, 2-way Cross-over Exploratory Clinical Trial Comparing TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on Lung Stiffness Reduction Assessed Through Area Under the Reactance Curve (AX) in COPD. [NCT04671355]	Phase 4	0 participants (Actual)	Interventional	2021-10-04	Withdrawn(stopped due to Continuing delays due to COVID-19 pandemic)
Randomized Double Control Study to Assess the Efficacy of Administering 1 ml of Glycopyrrolate With the Spinal Dose in Minimizing Nausea and Vomiting in Patients Undergoing Cesarean Section Under Spinal Anesthesia [NCT02872935]	Phase 4	22 participants (Actual)	Interventional	2015-05-15	Terminated
A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort® Turbohaler® in Healt [NCT02189304]	Phase 1	59 participants (Actual)	Interventional	2014-06-01	Completed
Benefits of Intramuscular Glycopyrrolate Premedication on Intubation With Rigid-videostylet (OptiScope® PM 201, KoMAC Co., Ltd, Seoul, Republic of Korea) [NCT03050242]		78 participants (Actual)	Interventional	2017-03-13	Completed
A Pharmacokinetic Feasibility Study on Ultibro Breezhaler, an Indacaterol-glycopyrronium Inhalation Powder Capsule, in Healthy Subjects [NCT04856098]	Phase 1	34 participants (Actual)	Interventional	2021-05-07	Completed
Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting [NCT05331651]	Phase 4	480 participants (Actual)	Interventional	2022-04-08	Completed
A Study to Assess the Pharmacokinetics and Safety of PT010 in Subjects With Moderate to Severe COPD Following Single and Repeat Dose Administration [NCT03250182]	Phase 1	30 participants (Actual)	Interventional	2017-08-11	Completed
Recovery From Optimal Neuromuscular Blockade in the Critically Ill: Randomized Control Trial [NCT03791801]		50 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia [NCT03322150]		2 participants (Actual)	Interventional	2017-10-01	Terminated(stopped due to The research was terminated because the recruitment of the study subjects was not smooth and the overseas training of the investigator was scheduled.)
Effect of Perioperative Use of Glycopyrrolate on Lung Function in Patients Under General Anesthesia [NCT05693246]		90 participants (Anticipated)	Interventional	2022-11-01	Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled 3-period Complete Cross-over Study to Assess the Bronchodilator Effects and Safety of Glycopyrronium Bromide (NVA237) (25 ug and 50 ug o.d.) in Asthma Patients. [NCT03137784]	Phase 2/Phase 3	148 participants (Actual)	Interventional	2017-05-04	Completed
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease [NCT01005901]	Phase 3	1,324 participants (Actual)	Interventional	2009-10-31	Completed
Effects of Long Acting Bronchodilators on CARDiac Autonomic Nervous System Control in Patients With COPD [NCT02872090]	Phase 4	42 participants (Actual)	Interventional	2016-03-31	Completed
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS) [NCT06067828]	Phase 3	180 participants (Anticipated)	Interventional	2023-10-24	Recruiting
A Prospective Trial to Assess How Glycopyrronium Cloths at the Amputation Site of Limb Amputees Changes the Severity of Hyperhidrosis and the Fit and Function of the Prosthetic Measured by Patient Reported Outcomes [NCT04924036]	Phase 2	20 participants (Anticipated)	Interventional	2021-09-27	Enrolling by invitation
Duration of Bronchoprotection of the Long Acting Muscarinic Antagonists Tiotropium and Glycopyrronium Against Methacholine Induced Bronchoconstriction [NCT02622243]	Phase 4	13 participants (Actual)	Interventional	2015-11-30	Completed
Intranasal Administration of Neostigmine and Glycopyrrolate for Bowel Evacuation [NCT00855283]	Phase 2	20 participants (Anticipated)	Interventional	2012-09-30	Completed
Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort [NCT02228473]		76 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Acute Effect of Aclidinium on Hyperinflation and Lung Volume Distribution in Severe COPD Patients [NCT02181023]	Phase 4	37 participants (Actual)	Interventional	2014-06-30	Completed
Comparison of Atropine Versus Glycopyrrolate in Preventing Spinal Anesthesia Induced Hypotension in Adult Patient Undergoing Major Lower Limb Orthopedic Surgeries [NCT03580889]	Phase 4	138 participants (Anticipated)	Interventional	2017-09-15	Recruiting
Outcomes in Real-life After Initation Of treatmeNt With Trixeo (Budesonide / Glycopyrronium / Formoterol), a Non-interventional, Multi-centre, Prospective Cohort Study in Italian Routine Care Setting [NCT05862545]		250 participants (Anticipated)	Observational	2023-06-01	Recruiting
Combined Dexmedetomidine and Glycopyrrolate Therapy for Prevention of Catheter Related Bladder Discomfort After Transurethral Bladder Surgery [NCT05013320]		0 participants (Actual)	Interventional	2021-09-01	Withdrawn(stopped due to We could not get the IRB approval)
A Randomized, Double-blind, Parallel Group, 52-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 in Patients With Poorly Controlled Asthma [NCT02127697]	Phase 3	0 participants (Actual)	Interventional	2015-03-31	Withdrawn
A Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003, Open-Label Spiriva® Res [NCT02347072]	Phase 3	80 participants (Actual)	Interventional	2015-02-01	Completed
IKANOS: A Prospective, Open-Label, Minimally Interventional Hybrid Study in the US Comparing Initiation of Breztri Maintenance Versus Any Non-Triple Inhaled Therapy at Discharge After a Hospitalization for a COPD Exacerbation [NCT05970263]	Phase 4	1,000 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
A Randomized, Double-blind, Positive and Placebo-controlled, Single-dose, Crossover Study of the Effects of CHF5993 pMDI (BDP/FF/GB) at the Proposed Therapeutic and Supratherapeutic Doses, on the Cardiovascular Safety in Healthy Subjects [NCT05830071]	Phase 1	95 participants (Actual)	Interventional	2023-03-29	Completed
Comparison of Time to Full Recovery From Muscle Paralysis (TOF>0.9) and Extubation Using Sugammadex Versus Neostigmine/Glycopyrrolate in Patients With Pulmonary Disease in the Outpatient Bronchoscopy Suite [NCT04606901]	Phase 4	58 participants (Actual)	Interventional	2021-04-08	Completed
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction [NCT05985343]	Phase 4	184 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Safety and Efficacy of High Resolution Manometry in Studying Colonic Motility and Iontophoretic Administration of Prokinetic Agents [NCT02574611]	Phase 1	0 participants (Actual)	Interventional	2015-10-13	Withdrawn(stopped due to No reportable findings are possible. The PI/Co-PI were unable to recruit participants for this study. One participant was consented but did not undergo any study procedure.)
A Phase 2, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis [NCT03880266]	Phase 2	72 participants (Actual)	Interventional	2019-02-22	Completed
The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD [NCT02576626]	Phase 4	40 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized, Double-blind, Placebo-controlled, 4 Period Incomplete Block Cross-over, Multi-center, Multiple Dose (7 Days) Dose-ranging Study to Assess the Efficacy and Safety of 4 Doses of NVA237 in Patients With Stable COPD, Compared to Seven Days Treat [NCT00501852]	Phase 2	83 participants (Actual)	Interventional	2007-07-31	Completed
A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neuro [NCT00491894]	Phase 3	137 participants (Actual)	Interventional	2007-03-31	Completed
A Feasibility Study of Glycopyrrolate in Comparison to Hyoscine Hydrobromide and Placebo in the Treatment of Hypersalivation Induced by Clozapine [NCT02613494]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2016-01-25	Completed
An Open-label, Uncontrolled, Multicenter Study to Evaluate the Safety, Local Tolerability, Systemic Exposure, and Efficacy of 1% Glycopyrronium Bromide (GPB) Cream in Adolescents With Severe Primary Axillary Hyperhidrosis [NCT05863104]	Phase 2	40 participants (Anticipated)	Interventional	2023-03-07	Recruiting
A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT00570778]	Phase 2	154 participants (Actual)	Interventional	2007-12-31	Completed
Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery [NCT03116997]	Phase 3	201 participants (Actual)	Interventional	2017-04-07	Completed
A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years [NCT03909165]	Phase 4	137 participants (Actual)	Interventional	2019-07-23	Completed
Intraoperative Video Laryngoscopy as Adjunct for Nerve Monitoring [NCT03742141]		125 participants (Actual)	Interventional	2018-10-17	Completed
Indacaterol 110µg/ Glycopyrronium 50µg (Ultibro®) Versus Tiotropium (Spiriva®) Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD [NCT02567214]	Phase 4	50 participants (Actual)	Interventional	2016-06-30	Completed
A Randomized, Double-blind, Placebo-controlled, 2-period, Cross-over Study to Assess the Efficacy and Safety of Differing Doses of NVA237 Administered Either Once Daily or Twice Daily, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Dise [NCT01119950]	Phase 2	388 participants (Actual)	Interventional	2010-04-30	Completed
Open-label, Randomized, Single-dose, Placebo-controlled, 4-way Crossover Study to Investigate the Pharmacokinetic Interaction of Glycopyrrolate and Formoterol in Healthy Subjects. [NCT01398111]	Phase 1	44 participants (Actual)	Interventional	2011-05-31	Completed
A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezh [NCT02693769]	Phase 2/Phase 3	2 participants (Actual)	Interventional	2016-07-31	Terminated(stopped due to Recruitment issues)
Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects [NCT02040597]	Phase 1	42 participants (Actual)	Interventional	2014-01-31	Completed
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Inhaled NVA237 Doses at Four Dose Levels in COPD Patients [NCT00545311]	Phase 1	40 participants (Actual)	Interventional	2007-07-31	Completed
A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium a [NCT00451217]	Phase 3	198 participants (Actual)	Interventional	2005-11-17	Completed
"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy" [NCT02375217]	Phase 4	56 participants (Actual)	Interventional	2014-10-31	Completed
A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease [NCT01917331]	Phase 3	1,368 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using [NCT01294787]	Phase 3	85 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of [NCT00473694]	Phase 3	182 participants (Actual)	Interventional	2005-11-28	Completed
A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of NVA237 (50µg o.d.) Using Tiotropium (18µg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Ob [NCT01119937]	Phase 3	211 participants (Actual)	Interventional	2010-05-31	Completed
A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive [NCT01202188]	Phase 3	2,144 participants (Actual)	Interventional	2010-09-30	Completed
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation [NCT06045364]	Phase 1/Phase 2	130 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Pharmacokinetics of Neostigmine and Glycopyrrolate After Intravenous and Transcutaneous Administration by Iontophoresis [NCT04027972]	Early Phase 1	13 participants (Actual)	Interventional	2020-03-09	Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD). [NCT00856193]	Phase 2	33 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Open-Label, Multiple Dose, Two-Period Crossover Study Evaluating Maximum Use 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% in Men and Women With Primary Axillary Hyperhidrosis [NCT04159610]	Phase 2	12 participants (Anticipated)	Interventional	2022-07-01	Not yet recruiting
A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture the Reasons for Switch to Triple Combination Therapy and to Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere™ in [NCT05915182]		200 participants (Anticipated)	Observational	2023-07-21	Recruiting
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease [NCT00929110]	Phase 3	1,066 participants (Actual)	Interventional	2009-06-30	Completed
A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Sev [NCT01120691]	Phase 3	2,224 participants (Actual)	Interventional	2010-04-30	Completed
Enhanced Recovery After Surgery in Elderly Patients: Effects of Sugammadex on Recovery After Anterior Cervical Spine Surgery [NCT04161508]		100 participants (Anticipated)	Interventional	2019-12-20	Not yet recruiting
Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block by Neostigmine or Sugammadex: A Randomized Controlled Trial [NCT05545280]	Phase 4	286 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry [NCT01479764]	Phase 3	154 participants (Actual)	Interventional	2011-12-02	Completed
A Prospective Non-interventional Study in Patients With Chronic Obstructive Pulmonary Disease That Evolve to Fixed Long-acting Muscarinic Antagonist/Long-acting beta2-agonist/Inhaled Corticosteroid Triple Therapy, Trimbow® [NCT03627858]		149 participants (Actual)	Observational	2018-08-01	Completed
Comparison of Anti-nausea and Vomiting Effect After Elective Surgery Undergoing General Anesthesia Between Glycopyrronium and Ondansetron: a Multi-center Study [NCT05265507]	Phase 4	480 participants (Anticipated)	Interventional	2022-03-21	Recruiting
An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease. [NCT03081156]	Phase 4	52 participants (Actual)	Interventional	2017-03-27	Completed
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Determine the Effect of QVA149 on Mean 24-hours Heart Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT00558285]	Phase 2	257 participants (Actual)	Interventional	2007-11-30	Completed
A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess Efficacy and Safety of 3 Free Doses of Glycopyrrolate With Beclomethasone/Formoterol pMDI for the Treatment of COPD Patients [NCT01476813]	Phase 2	281 participants (Actual)	Interventional	2012-03-31	Completed
[NCT01768780]		58 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery [NCT03939923]	Phase 4	84 participants (Actual)	Interventional	2019-05-01	Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD [NCT01154127]	Phase 3	108 participants (Actual)	Interventional	2010-06-30	Completed
A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary D [NCT01315249]	Phase 3	523 participants (Actual)	Interventional	2011-03-31	Completed
The Effect of Glycopyrronium and Indacaterol, as Monotherapy and in Combination, on the Methacholine Dose-response Curve [NCT02953041]	Phase 4	31 participants (Actual)	Interventional	2016-10-31	Completed
A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis [NCT02016885]	Phase 2	198 participants (Actual)	Interventional	2013-11-30	Completed
Decision Support for Intraoperative Low Blood Pressure [NCT02726620]		22,435 participants (Actual)	Interventional	2017-01-05	Completed
A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 μg o.d.) Using Tiotropium (5 μg o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Dis [NCT01837927]	Phase 3	0 participants (Actual)	Interventional	2014-04-30	Withdrawn
A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrro [NCT04320342]	Phase 3	2,934 participants (Anticipated)	Interventional	2022-04-28	Recruiting
An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis [NCT02553798]	Phase 3	564 participants (Actual)	Interventional	2015-08-31	Completed
The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit. [NCT04554589]	Phase 1	80 participants (Anticipated)	Interventional	2020-09-14	Not yet recruiting
A Pilot Study to Measure and Treat Antidepressant-Induced Excessive Sweating With Glycopyrrolate (AIDES-G) [NCT01588717]	Phase 1	5 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to PI left institution)
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide [NCT05222529]	Phase 2	42 participants (Anticipated)	Interventional	2022-08-29	Recruiting
Comparison of Rocuronium and Org25969 With Cisatracurium and Neostigmine When Neuromuscular Block is Reversed at Reappearance of T2 [NCT00451100]	Phase 3	84 participants (Actual)	Interventional	2005-11-10	Completed
Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children [NCT00315536]	Phase 2	63 participants (Actual)	Interventional	2006-05-31	Completed
An Investigation of the Efficacy, Tolerability and Safety of a Range of Doses of Orally Inhaled Glycopyrronium Bromide (PSX1002-GB pMDI) in Male and Female Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease [NCT01703624]	Phase 2	37 participants (Actual)	Interventional	2013-05-31	Completed
A 26-week Multi-center Randomized Double-blind Study to Compare Efficacy and Safety of NVA237 Versus Placebo as an add-on to Maintenance Therapy With Fixed-dose Combination Salmeterol/Fluticasone Propionate in COPD Patients With Moderate to Severe Airflow [NCT01757015]	Phase 3	0 participants (Actual)	Interventional	2013-04-30	Withdrawn
Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia [NCT04401345]	Phase 4	258 participants (Actual)	Interventional	2020-06-01	Completed
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation [NCT01191398]		52 participants (Actual)	Interventional	2010-06-30	Completed
A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Lab [NCT02433834]	Phase 2	248 participants (Actual)	Interventional	2015-05-27	Completed
Pharmacokinetic Formulation Feasibility Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Easyhaler Test Products and Reference Product Ultibro Breezhaler [NCT05288075]	Phase 1	24 participants (Actual)	Interventional	2022-02-28	Completed
Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy - a Randomized Controlled Trial [NCT03357393]		150 participants (Actual)	Interventional	2016-04-04	Completed
Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient [NCT04087590]	Phase 2	35 participants (Anticipated)	Interventional	2020-01-14	Recruiting
Open Label, Uncontrolled, Non-randomized, Single Dose, Scintigraphic Study to Investigate Lung Deposition of Inhaled 99mTc Radiolabelled CHF5993 pMDI in Healthy Volunteers, Asthmatic and COPD Patients [NCT02975843]	Phase 1	28 participants (Actual)	Interventional	2016-11-21	Completed
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation [NCT01697696]	Phase 3	511 participants (Actual)	Interventional	2012-10-31	Completed
A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Using Tiotropium Plus Formoterol as Control [NCT01574651]	Phase 3	934 participants (Actual)	Interventional	2012-05-31	Completed
Sugammadex Versus Neostigmine for Reversal of Rocuronium-induced Neuromuscular Blockade: A Study of Thoracic Surgical Patients [NCT03168308]	Phase 4	92 participants (Actual)	Interventional	2017-09-26	Completed
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy [NCT03111121]	Phase 4	84 participants (Anticipated)	Interventional	2017-05-04	Recruiting
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA [NCT06075095]	Phase 3	240 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery [NCT01748643]	Phase 4	60 participants (Actual)	Interventional	2013-04-30	Completed
A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD. [NCT01699685]	Phase 3	79 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease [NCT02371629]	Phase 4	776 participants (Actual)	Interventional	2015-06-24	Completed
An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy C [NCT01613690]	Phase 1	48 participants (Actual)	Interventional	2010-06-30	Completed
Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Rest Blockade With Sugammadex [NCT01453530]	Phase 4	30 participants (Anticipated)	Interventional	2011-10-31	Recruiting
A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02236611]	Phase 4	1,036 participants (Actual)	Interventional	2014-09-26	Completed
Determinants of Chronotropic Incompetence in Patients With Heart Failure and a Preserved Ejection Fraction (HFpEF) [NCT02524145]		40 participants (Actual)	Interventional	2015-06-30	Completed
A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptom [NCT01985334]	Phase 4	4,389 participants (Actual)	Interventional	2014-02-14	Completed
Multicenter, Randomized, Blinded, Two-period Cross-over Study to Assess the Effect of Glycopyrronium (44 Micrograms QD) Versus Tiotropium (18 Micrograms QD) on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD [NCT01959516]	Phase 4	124 participants (Actual)	Interventional	2014-02-28	Completed
A Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003 and Placebo MDI [NCT02347085]	Phase 3	43 participants (Actual)	Interventional	2015-02-01	Completed
An Open-Label, Multi-Center, Dose Indicator Study of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) in Adult Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) [NCT02268396]	Phase 3	138 participants (Actual)	Interventional	2014-11-30	Completed
Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery: A Double-Blinded Randomized Controlled Trial. [NCT02996591]	Phase 4	36 participants (Actual)	Interventional	2017-01-31	Completed
A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001 in Japanese Healthy Subjects [NCT02196714]	Phase 1	24 participants (Actual)	Interventional	2014-07-31	Completed
Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care [NCT04737655]	Phase 4	200 participants (Anticipated)	Interventional	2021-02-15	Not yet recruiting
Single-dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Patients With COPD [NCT02951312]	Phase 2	12 participants (Actual)	Interventional	2009-05-31	Completed
A Randomized, Blinded-assessor, Single Center Study to Determine if Administration of Sugammadex, When Used to Reverse Deep Neuromuscular Blockade (NMB) After Open Abdominal Surgery, Impacts Hospital Efficiency [NCT02860507]	Phase 4	50 participants (Actual)	Interventional	2016-08-31	Completed
Open Label, Uncontrolled, Non-randomized, Single Dose, Scintigraphic Study to Investigate Lung Deposition of Inhaled 99mTc Radiolabelled TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients [NCT03795350]	Phase 1	19 participants (Actual)	Interventional	2019-01-14	Terminated(stopped due to In light of the cessation of non-essential clinical activities at CPU due to the COVID-19 pandemic, the sponsor has determined to terminate the study early.)
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures [NCT03322657]	Phase 4	69 participants (Actual)	Interventional	2017-11-14	Completed
An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging [NCT03513757]	Phase 4	40 participants (Actual)	Interventional	2018-03-04	Completed
A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease [NCT02382198]	Phase 2	28 participants (Anticipated)	Interventional	2016-07-31	Recruiting
A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients [NCT02566031]	Phase 4	379 participants (Actual)	Interventional	2013-03-23	Completed
[NCT02370433]	Phase 1	20 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy: a Randomized Clinical Trial [NCT02327923]	Phase 4	90 participants (Actual)	Interventional	2015-01-31	Completed
A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active [NCT01490125]	Phase 3	247 participants (Actual)	Interventional	2011-10-31	Completed
A Multicenter, Randomized, Blinded, Active-controlled, Parallel-group Study to Compare the Efficacy, Tolerability and Safety of NVA237 Compared to Tiotropium Added on to Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease [NCT01513460]	Phase 3	773 participants (Actual)	Interventional	2012-04-30	Completed
A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, Two-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patien [NCT02487498]	Phase 3	355 participants (Actual)	Interventional	2015-07-27	Completed
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhydrosis [NCT02530281]	Phase 3	344 participants (Actual)	Interventional	2015-07-31	Completed
Xenon MRI Probing vEntilation Response to Triple Therapy (QVM149) [NCT04206761]	Phase 3	0 participants (Actual)	Interventional	2021-12-01	Withdrawn(stopped due to issues related to Covid-19 restrictions/shutdowns)
Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery [NCT03513406]	Phase 3	7 participants (Actual)	Interventional	2018-03-15	Completed
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer) [NCT02276222]	Phase 3	1,087 participants (Actual)	Interventional	2014-10-31	Completed
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation [NCT01682863]	Phase 3	614 participants (Actual)	Interventional	2012-10-31	Completed
A Study to Compare the Efficacy and Safety of Once Daily QVA149 Versus the Once Daily Concurrent Administration of QAB149 Plus NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [NCT01529632]	Phase 3	193 participants (Actual)	Interventional	2012-05-31	Completed
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airf [NCT01712516]	Phase 3	1,001 participants (Actual)	Interventional	2012-12-31	Completed
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients [NCT01709864]	Phase 3	440 participants (Actual)	Interventional	2012-11-30	Completed
Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia [NCT03322098]		54 participants (Actual)	Interventional	2017-10-16	Completed
An Open-label Study to Evaluate the Efficacy and Safety of Different Methods of Application of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis [NCT04906655]	Phase 2	120 participants (Actual)	Interventional	2020-10-01	Completed
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients [NCT01715298]	Phase 3	432 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis [NCT02129660]	Phase 2	105 participants (Actual)	Interventional	2014-04-30	Completed
Effect of Anesthetic Choice (Sevoflurane Versus Desflurane) on Speed and Sustained Nature of Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block [NCT01199237]	Phase 4	107 participants (Actual)	Interventional	2010-08-31	Completed
A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary [NCT02512302]	Phase 1	30 participants (Actual)	Interventional	2015-10-31	Completed
A Randomized, Controlled, Parallel-group, Double-blind Trial of Sugammadex or Usual Care (Neostigmine or Spontaneous Recovery) for Reversal of Rocuronium- or Vecuronium-induced Neuromuscular Blockade in Patients Receiving Thromboprophylaxis and Undergoing [NCT01422304]	Phase 3	1,198 participants (Actual)	Interventional	2011-10-12	Completed
Effects of the Addition of a Prokinetic Agent to Thrice Weekly Bowel Care in Individuals With SCI [NCT04671030]	Phase 1	6 participants (Actual)	Interventional	2018-01-15	Completed
A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, 2-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients [NCT02487446]	Phase 3	357 participants (Actual)	Interventional	2015-07-28	Completed
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airf [NCT01727141]	Phase 3	1,042 participants (Actual)	Interventional	2012-11-30	Completed
Sugammadex Reversal VS Neostigmine and Glycopyrrolate Competitive Antagonism of Neuromuscular Blockade for GI-2 Recovery After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial for Quality Improvement [NCT06112353]	Phase 4	128 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR® pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dos [NCT02296411]	Phase 2	98 participants (Actual)	Interventional	2014-11-30	Completed
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) [NCT02202616]	Phase 4	401 participants (Actual)	Interventional	2014-08-27	Completed
Randomized, Open-label, Three Arms Study to Evaluate the Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources in Patients With ≥ 18 Years Old (TRIVID Study) [NCT04937543]	Phase 2	50 participants (Actual)	Interventional	2021-06-28	Active, not recruiting
A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo [NCT02343458]	Phase 3	1,756 participants (Actual)	Interventional	2015-03-30	Completed
A Double-blind, Randomized, Parallel Group Study to Compare Rocuronium Reversal With Sugammadex (Bridion®) Versus Neostigmine/Glycopyrrolate and the Incidence of Urinary Retention After Elective Ambulatory Posterior Lumbar Laminectomy [NCT05887375]	Phase 4	118 participants (Anticipated)	Interventional	2023-08-03	Enrolling by invitation
A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared [NCT01854658]	Phase 3	1,615 participants (Actual)	Interventional	2013-07-31	Completed
Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program [NCT03364829]	Phase 4	50 participants (Anticipated)	Interventional	2016-01-01	Recruiting
A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD [NCT01709903]	Phase 3	744 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized Clinical Study to Compare Low Dose of Sugammadex to Standard Dose of Neostigmine and Glycopyrrolate for the Reversal of Rocuronium Induced Moderate Neuromuscular Block [NCT05718934]	Phase 4	144 participants (Anticipated)	Interventional	2022-11-08	Recruiting
A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis [NCT02530294]	Phase 3	353 participants (Actual)	Interventional	2015-08-31	Completed
A 12-week Treatment, Randomized, Blinded, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 (50 µg o.d.) Compared to Tiotropium (18 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT01613326]	Phase 3	657 participants (Actual)	Interventional	2012-06-30	Completed
A Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) [NCT02233543]	Phase 4	38 participants (Actual)	Interventional	2014-11-30	Completed
A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD [NCT01604278]	Phase 3	449 participants (Actual)	Interventional	2012-05-31	Completed
A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study) [NCT01922271]	Phase 4	152 participants (Actual)	Interventional	2013-08-31	Completed
A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease [NCT01566604]	Phase 3	460 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00451217 (5) [back to overview]	Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Transfer to the Recovery Room After Extubation
NCT00451217 (5) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8
NCT00451217 (5) [back to overview]	Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Discharge From the Recovery Room
NCT00451217 (5) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9.
NCT00451217 (5) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]	Number of Participants Able to Perform a 5-second Head Lift
NCT00473694 (11) [back to overview]	Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]	Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]	Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]	Number of Participants Experiencing General Muscle Weakness
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]	Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00491894 (5) [back to overview]	Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS)
NCT00491894 (5) [back to overview]	Parent/Caregiver's Global Assessment of Treatment
NCT00491894 (5) [back to overview]	Investigator's Global Assessment of Treatment
NCT00491894 (5) [back to overview]	Parent/Caregiver's Assessment of the Extent of Drooling Using Visual Analog Scale (VAS)
NCT00491894 (5) [back to overview]	Parent/Caregiver's Assessment of the Extent of Drooling Using VAS
NCT00501852 (2) [back to overview]	Least Squares Means of FEV1 (L) at Day 1, by Timepoint
NCT00501852 (2) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment
NCT00510510 (2) [back to overview]	Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00510510 (2) [back to overview]	Least Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day
NCT00558285 (7) [back to overview]	Change From Baseline in QTc (Fridericia's Formula) at Day 7
NCT00558285 (7) [back to overview]	Change From Baseline in QTc (Fridericia's Formula) at Day 14
NCT00558285 (7) [back to overview]	Change From Baseline in QTc (Fridericia's Formula) at Day 1
NCT00558285 (7) [back to overview]	Change From Baseline in Mean 24 Hour Heart Rate at Day 14
NCT00558285 (7) [back to overview]	Change From Baseline in Mean 24 Hour Heart Rate at Day 1
NCT00558285 (7) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14
NCT00558285 (7) [back to overview]	Trough Forced Vital Capacity (FVC) at Day 1 and Day 14
NCT00570778 (3) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7
NCT00570778 (3) [back to overview]	Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve (AUC) 5 Minutes-12 Hours at Day 7
NCT00570778 (3) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events
NCT00856193 (4) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14
NCT00856193 (4) [back to overview]	Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14
NCT00856193 (4) [back to overview]	Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14
NCT00856193 (4) [back to overview]	Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)
NCT00929110 (20) [back to overview]	Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
NCT00929110 (20) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52
NCT00929110 (20) [back to overview]	Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52
NCT00929110 (20) [back to overview]	Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)
NCT00929110 (20) [back to overview]	"Percentage of Days Able to Perform Usual Daily Activities During the Study (Baseline to Week 52)"
NCT00929110 (20) [back to overview]	"Percentage of Days With no Daytime Symptoms During the Study (Baseline to Week 52)"
NCT00929110 (20) [back to overview]	"Percentage of Nights With no Nighttime Awakenings During the Study (Baseline to Week 52)"
NCT00929110 (20) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)
NCT00929110 (20) [back to overview]	Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)
NCT00929110 (20) [back to overview]	Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52
NCT00929110 (20) [back to overview]	Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
NCT00929110 (20) [back to overview]	Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
NCT00929110 (20) [back to overview]	Transition Dyspnea Index (TDI) at Week 26
NCT00929110 (20) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT00929110 (20) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
NCT00929110 (20) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
NCT00929110 (20) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52
NCT00929110 (20) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52
NCT00929110 (20) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52
NCT00929110 (20) [back to overview]	Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
NCT01005901 (17) [back to overview]	Trough FEV1 and FVC at Day 1 and Week 26
NCT01005901 (17) [back to overview]	Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period
NCT01005901 (17) [back to overview]	Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period
NCT01005901 (17) [back to overview]	Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period
NCT01005901 (17) [back to overview]	Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)
NCT01005901 (17) [back to overview]	Mean Daily Total Symptom Score Over the 26 Week Treatment Period
NCT01005901 (17) [back to overview]	Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment
NCT01005901 (17) [back to overview]	Number of Participants With Adverse Events, Death, and Serious or Clinically Significant Adverse Events or Related Discontinuations
NCT01005901 (17) [back to overview]	Forced Vital Capacity (FVC) at Each Time-point on Day 1 and Week 26
NCT01005901 (17) [back to overview]	FEV1 at Each Time-point on Day 1 and Week 26
NCT01005901 (17) [back to overview]	FEV1 Area Under the Curve (AUC) (5 Min - 12 Hour) at Day 1, Week 12 and Week 26
NCT01005901 (17) [back to overview]	FEV1 Area Under Curve (AUC) (5 Min - 23 Hour 45 Min) at Week 12 and Week 26
NCT01005901 (17) [back to overview]	Change in 24-hourly Mean Heart Rate at Day 1, Week 12 and Week 26
NCT01005901 (17) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks
NCT01005901 (17) [back to overview]	Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment
NCT01005901 (17) [back to overview]	Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment
NCT01005901 (17) [back to overview]	Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period
NCT01119937 (11) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events or Death
NCT01119937 (11) [back to overview]	Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period
NCT01119937 (11) [back to overview]	Change in St. George Respiratory Questionnaire From Baseline
NCT01119937 (11) [back to overview]	Change in Pre-dose FVC From Baseline
NCT01119937 (11) [back to overview]	Change in Pre-dose FEV1 From Baseline
NCT01119937 (11) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period
NCT01119937 (11) [back to overview]	Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period
NCT01119937 (11) [back to overview]	Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period
NCT01119937 (11) [back to overview]	Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period
NCT01119937 (11) [back to overview]	Number of Patients With Moderate or Severe COPD Exacerbations
NCT01119937 (11) [back to overview]	Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation
NCT01119950 (33) [back to overview]	Trough Forced Vital Capacity on Days 1, 7 and 14
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Trough Forced Expiratory Volume in One Second by Treatment at Day 28
NCT01119950 (33) [back to overview]	Trough Forced Vital Capacity After 28 Days of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment
NCT01119950 (33) [back to overview]	Mean Daily Use of Rescue Medication by Treatment at Different Time Points
NCT01119950 (33) [back to overview]	Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14
NCT01119950 (33) [back to overview]	Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14
NCT01119950 (33) [back to overview]	Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment
NCT01119950 (33) [back to overview]	Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237
NCT01119950 (33) [back to overview]	Peak Forced Expiratory Volume in One Second at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment
NCT01119950 (33) [back to overview]	Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment
NCT01119950 (33) [back to overview]	Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28
NCT01120691 (13) [back to overview]	Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period.
NCT01120691 (13) [back to overview]	Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics
NCT01120691 (13) [back to overview]	Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points
NCT01120691 (13) [back to overview]	Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period
NCT01120691 (13) [back to overview]	Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period.
NCT01120691 (13) [back to overview]	Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period
NCT01120691 (13) [back to overview]	Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.
NCT01120691 (13) [back to overview]	Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics
NCT01120691 (13) [back to overview]	Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period
NCT01120691 (13) [back to overview]	Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period
NCT01120691 (13) [back to overview]	Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium
NCT01120691 (13) [back to overview]	Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium
NCT01120691 (13) [back to overview]	St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment
NCT01154127 (9) [back to overview]	Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment
NCT01154127 (9) [back to overview]	Specific Airways Conductance (SGaw)
NCT01154127 (9) [back to overview]	Slow Vital Capacity (SVC) and Total Lung Capacity (TLC)
NCT01154127 (9) [back to overview]	Peak and Trough (24 h Post Dose) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)
NCT01154127 (9) [back to overview]	Inspiratory Capacity (IC) at Rest (1 Hour Post Dose) and at Peak (End of Exercise) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment
NCT01154127 (9) [back to overview]	Leg Discomfort (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment
NCT01154127 (9) [back to overview]	Exertional Dyspnea (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment
NCT01154127 (9) [back to overview]	Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) on Treatment Day 1
NCT01154127 (9) [back to overview]	Isotime Inspiratory Capacity (IC) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment
NCT01191398 (2) [back to overview]	Monitoring of Adverse Events During Study Administration
NCT01191398 (2) [back to overview]	Difference in Salivary Flow Rate (ml/Min) Between Study Groups
NCT01199237 (5) [back to overview]	Time From Potent Inhaled Anesthetic Discontinuation to First Response to Command (T1)
NCT01199237 (5) [back to overview]	Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis.
NCT01199237 (5) [back to overview]	Time From Anesthetic Discontinuation to First Ability to Swallow
NCT01199237 (5) [back to overview]	Nausea and Vomiting
NCT01199237 (5) [back to overview]	Nausea and Vomiting
NCT01202188 (23) [back to overview]	Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours at Day 1 and Week 26
NCT01202188 (23) [back to overview]	"Percentage of Days Able to Perform Usual Daily Activities Over 26 Weeks"
NCT01202188 (23) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score at Week 26
NCT01202188 (23) [back to overview]	Percentage of Patients With at Least One Moderate or Severe COPD Exacerbation Over the 26 Week Treatment Period
NCT01202188 (23) [back to overview]	Baseline Transitional Dyspnea Index (BDI/TDI) Focal Score at Week 12 and Week 26
NCT01202188 (23) [back to overview]	Change From Baseline (BL) in the Daytime and Night Time Rescue Medication Use (Number of Puffs) Over 26 Weeks
NCT01202188 (23) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication at Week 12 and Week 26
NCT01202188 (23) [back to overview]	Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment
NCT01202188 (23) [back to overview]	Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment With QVA149 Compared to Tiotropium
NCT01202188 (23) [back to overview]	Percentage of Participants With COPD Exacerbations Requiring Hospitalization or Treatment With Systemic Corticosteroids and/or Antibiotics But no Hospitalization
NCT01202188 (23) [back to overview]	Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes at Week 26
NCT01202188 (23) [back to overview]	St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 26
NCT01202188 (23) [back to overview]	Rate of Moderate or Severe COPD Exacerbation
NCT01202188 (23) [back to overview]	Percentage of Patients With a Clinically Important Improvement of at Least 1 Point in TDI Focal Score After 26 Weeks of Treatment
NCT01202188 (23) [back to overview]	Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment With QVA149, QAB149 and NVA237 Compared to Placebo
NCT01202188 (23) [back to overview]	Percentage of Patients With a Clinically Important Improvement From Baseline of at Least 4 Units in the SGRQ Total Score After 26 Weeks of Treatment
NCT01202188 (23) [back to overview]	24 Hour Holter Monitoring in a Subset of Patients
NCT01202188 (23) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Over 26 Weeks
NCT01202188 (23) [back to overview]	"Percentage of Nights With No Night Time Awakenings Over 26 Weeks"
NCT01202188 (23) [back to overview]	"Percentage of Days With no Rescue Medication Use Over 26 Weeks"
NCT01202188 (23) [back to overview]	"Percentage of Days With No Daytime Symptoms Over 26 Weeks"
NCT01202188 (23) [back to overview]	Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours at Day 1 and Week 26
NCT01202188 (23) [back to overview]	St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 and 26 Weeks of Treatment
NCT01294787 (13) [back to overview]	Pulmonary Function Test (RV) Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Pulmonary Function Test (SGaw) Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Pulmonary Function Test Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Dynamic Inspiratory Capacity Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Exercise Endurance Comparison Between QVA149 and Tiotropium Groups
NCT01294787 (13) [back to overview]	Exercise Endurance Time Comparison After a Single Dose of QVA149 Versus Placebo
NCT01294787 (13) [back to overview]	Exercise Tolerance Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Exertional Dyspnea Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Leg Discomfort During Exercise Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Spirometry After Three Weeks of Treatment on Patients Not Exercising
NCT01294787 (13) [back to overview]	Trough 24 Hour Post Dose Forced Expiratory Volume in One Second Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Trough 24 Hour Post Dose Inspiratory Capacity Comparison Between QVA149 and Placebo Groups
NCT01294787 (13) [back to overview]	Pulmonary Function Test (FRC) Comparison Between QVA149 and Placebo Groups
NCT01315249 (11) [back to overview]	Number of Participants With Adverse Events
NCT01315249 (11) [back to overview]	Mean Change From Baseline in Daily Number of Puffs of Rescue Medication
NCT01315249 (11) [back to overview]	Inspiratory Capacity (IC) at All-time Points (26 Weeks)
NCT01315249 (11) [back to overview]	Inspiratory Capacity (IC) at All-time Points (12 Weeks)
NCT01315249 (11) [back to overview]	Forced Vital Capacity at All-time Points (Week 26)
NCT01315249 (11) [back to overview]	Forced Vital Capacity at All-time Points (Week 12)
NCT01315249 (11) [back to overview]	Change From Baseline in Symptom Scores Reported Using the Ediary
NCT01315249 (11) [back to overview]	Standardized Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12 Hours
NCT01315249 (11) [back to overview]	Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12
NCT01315249 (11) [back to overview]	Focal Score of the Transitional Dyspnea Index (TDI)
NCT01315249 (11) [back to overview]	Total Score of the St. George's Respiratory Questionnaire (SGRQ-C)
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 14 Days After Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants With One or More Postoperative Anemia Adverse Events With Onset Within 72 Hours After Study Drug Administration
NCT01422304 (13) [back to overview]	Percent Change From Baseline in Prothrombin Time (International Normalized Ratio) (PT[INR]) at 10 and 60 Minutes Post Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Major Events of Bleeding With Onset Within 14 Days After Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Venous Thromboembolic (VTE) Events With Onset Within 14 Days After Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Events of Anaphylaxis With Onset Within 14 Days After Study Drug Administration
NCT01422304 (13) [back to overview]	Number of Participants Requiring Any Postoperative Transfusion
NCT01422304 (13) [back to overview]	Number of Participants With One or More Adjudicated Major Events of Bleeding With Onset Within 24 Hours After Study Drug Administration
NCT01422304 (13) [back to overview]	Percent Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at 10 and 60 Minutes Post Study Drug Administration
NCT01422304 (13) [back to overview]	Total Transfusion Volume in Participants Who Required Postoperative Transfusion
NCT01422304 (13) [back to overview]	Postoperative Drainage Volume Within 24 Hours After Study Drug Administration
NCT01422304 (13) [back to overview]	Postoperative Changes in Hgb Concentrations Using the Bleeding Index
NCT01479764 (2) [back to overview]	Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry
NCT01479764 (2) [back to overview]	Time From Start of Study Drug Administration to Operating Room Discharge-ready
NCT01490125 (6) [back to overview]	Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Tiotropium
NCT01490125 (6) [back to overview]	Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo
NCT01490125 (6) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Used Over the 6 Weeks of Treatment
NCT01490125 (6) [back to overview]	Standardized Forced Vital Capacity (FVC) Area Under the Curve (AUC) 5min-4 Hrs After First Dose and 6 Weeks of Treatment With QVA149 Compared to Placebo and Tiotropium
NCT01490125 (6) [back to overview]	Change From Baseline in The Capacity of Daily Living During the Morning (CDLM) Score Averaged Over 6 Weeks of Treatment
NCT01490125 (6) [back to overview]	Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 5min-4h After First Dose and 6 Weeks of Treatment With QVA149 Compared to Placebo and Tiotropium
NCT01513460 (7) [back to overview]	Mean Percentage of Nights With 'no Nighttime Awakenings'
NCT01513460 (7) [back to overview]	Mean Percentage of Days With Performance of Usual Activities
NCT01513460 (7) [back to overview]	Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment
NCT01513460 (7) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use
NCT01513460 (7) [back to overview]	Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)
NCT01513460 (7) [back to overview]	Change From Baseline in Mean Trough FEV1
NCT01513460 (7) [back to overview]	Change From Baseline in Mean Trough FEV1 (Flu/Sal Versus NVA237/Tiotropium+Flu/Sal)
NCT01529632 (7) [back to overview]	Time Course of Forced Expiratory Volume in One Second (FEV1) (Pre-dose to 4 Hours Post Dose) on Day 28
NCT01529632 (7) [back to overview]	Peak Forced Expiratory Volume in 1 Second (FEV1) on Days 1 and 28 Post-dose
NCT01529632 (7) [back to overview]	Change From Baseline in the Mean Daily, (Daytime and Nighttime Combined) Number of Puffs of Rescue Medication Used Over 28 Days of Treatment
NCT01529632 (7) [back to overview]	Change From Baseline in Percentage of Days With 'no Daytime Symptoms' Over 28 Days of Treatment
NCT01529632 (7) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-4 Hours at Day 28
NCT01529632 (7) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-4 Hours at Day 1
NCT01529632 (7) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment
NCT01566604 (11) [back to overview]	Change From Baseline in Daily Rescue Medication Use (Number of Puffs)
NCT01566604 (11) [back to overview]	Number of Moderate and Severe COPD Exacerbations
NCT01566604 (11) [back to overview]	Time to First Moderate or Severe COPD Exacerbation
NCT01566604 (11) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1)
NCT01566604 (11) [back to overview]	24h Trough FEV1
NCT01566604 (11) [back to overview]	Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)
NCT01566604 (11) [back to overview]	FEV1 and Forced Vital Capacity (FVC)
NCT01566604 (11) [back to overview]	Peak FEV1
NCT01566604 (11) [back to overview]	Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose
NCT01566604 (11) [back to overview]	The Total Score of the St George's Respiratory Questionnaire (SGRQ)
NCT01566604 (11) [back to overview]	Transition Dyspnea Index (TDI) Score
NCT01574651 (9) [back to overview]	Trough FEV1 at Baseline and Week 26
NCT01574651 (9) [back to overview]	Percent of Participants With at Least One Exacerbation Requiring Hospitalization
NCT01574651 (9) [back to overview]	Percent of Participants With at Least One Exacerbation Requiring Systemic Corticosteroids and/or Antibiotics Over 26 Weeks
NCT01574651 (9) [back to overview]	Time- Event Analysis, Number of Participants With at Least One COPD Exacerbation (Moderate or Severe) During the Treatment Period
NCT01574651 (9) [back to overview]	"Symptoms Score Reported by the Patients Using Part I Symptoms of SGRO-C"
NCT01574651 (9) [back to overview]	FEV1 30 Min After the Morning Dose at Baseline and Week 26
NCT01574651 (9) [back to overview]	St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis).
NCT01574651 (9) [back to overview]	Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment.
NCT01574651 (9) [back to overview]	St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Superiority Analysis).
NCT01604278 (10) [back to overview]	Change From Baseline in Mean Daily Total and Individual Symptom Scores
NCT01604278 (10) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
NCT01604278 (10) [back to overview]	FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose
NCT01604278 (10) [back to overview]	Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks
NCT01604278 (10) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score
NCT01604278 (10) [back to overview]	Trough Forced Expiratory Volume at 1 Second (FEV1)
NCT01604278 (10) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT01604278 (10) [back to overview]	Inspiratory Capacity (IC) at Individual Time-points
NCT01604278 (10) [back to overview]	Forced Vital Capacity (FVC) at Individual Time-points
NCT01604278 (10) [back to overview]	FEV1 at Individual Time-points
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)
NCT01613326 (13) [back to overview]	Transition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4
NCT01613326 (13) [back to overview]	Peak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12
NCT01613326 (13) [back to overview]	St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)
NCT01613326 (13) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment
NCT01613326 (13) [back to overview]	Event Free Rate at Weeks 4, 8 and 12 After Treatment
NCT01613326 (13) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit
NCT01613326 (13) [back to overview]	Forced Vital Capacity (FVC) at Each Time-point by Visit
NCT01613326 (13) [back to overview]	Inspiratory Capacity (IC) at Each Time-point, by Visit
NCT01613326 (13) [back to overview]	Mean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period
NCT01613326 (13) [back to overview]	Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose
NCT01682863 (8) [back to overview]	Time to Premature Discontinuation of Treatment
NCT01682863 (8) [back to overview]	Change From Baseline in 1 Hour Post-dose FEV1 Measurements
NCT01682863 (8) [back to overview]	Change From Baseline in FVC Measurement at All Post-baseline Time Points
NCT01682863 (8) [back to overview]	Change From Baseline in Pre-dose Trough FEV1
NCT01682863 (8) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events, and Death
NCT01682863 (8) [back to overview]	Change From Baseline in Mean Total Daily Symptom Scores
NCT01682863 (8) [back to overview]	Change From Baseline in the Daily Number of Puffs of Rescue Medication Over the 52 Week Period
NCT01682863 (8) [back to overview]	Percentage of Participants Experiencing Moderate or Severe COPD Exacerbation
NCT01697696 (9) [back to overview]	Change From Baseline in Pre-dose Forced Vital Capacity (FVC) at All Post-baseline Timepoints
NCT01697696 (9) [back to overview]	Change From Baseline in Pre-dose Forced Expiratory Volume (FEV1) in One Second at All Post Baseline Timepoints
NCT01697696 (9) [back to overview]	Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52
NCT01697696 (9) [back to overview]	Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate
NCT01697696 (9) [back to overview]	Time to First COPD Exacerbation (Moderate or Severe).
NCT01697696 (9) [back to overview]	Time to Treatment Discontinuation
NCT01697696 (9) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
NCT01697696 (9) [back to overview]	Change From Baseline in COPD Symptoms
NCT01697696 (9) [back to overview]	Change From Baseline in COPD Symptoms
NCT01699685 (6) [back to overview]	Inspiratory Capacity (IC)
NCT01699685 (6) [back to overview]	Inspiratory Capacity (IC) Peak Value
NCT01699685 (6) [back to overview]	Total Lung Capacity (TLC)
NCT01699685 (6) [back to overview]	Airway Resistance (Raw)
NCT01699685 (6) [back to overview]	Forced Expiratory Volume in One Second (FEV1)
NCT01699685 (6) [back to overview]	Forced Volume Capacity (FVC)
NCT01709864 (15) [back to overview]	Change From Baseline of Morning and Nighttime Symptom Scores at Week 12
NCT01709864 (15) [back to overview]	"Percentage of Days Able to Perform Usual Daily Activities"
NCT01709864 (15) [back to overview]	Change From Baseline of Daily Symptom Scores
NCT01709864 (15) [back to overview]	"Percentage of Nights With no Nighttime Awakenings"
NCT01709864 (15) [back to overview]	"Percentage of Days With no Daytime Symptoms"
NCT01709864 (15) [back to overview]	Breathlessness Assessed by Transition Dyspnea Index (TDI) Focal Score at Week 12
NCT01709864 (15) [back to overview]	Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire
NCT01709864 (15) [back to overview]	Change From Baseline of Forced Vital Capacity (FVC) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)
NCT01709864 (15) [back to overview]	Change From Baseline of Forced Expiratory Volume in One Second (FEV1) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)
NCT01709864 (15) [back to overview]	Change From Baseline in Trough FEV1 and Pre-dose Trough FEV1 by Visit
NCT01709864 (15) [back to overview]	Change From Baseline in FEV1 AUC (0-12H) at Day 1 and FEV1 AUC (0-4h), AUC (4-8h), AUC (8-12h) at Day 1 and Week 12 (Day 85)
NCT01709864 (15) [back to overview]	The Average Number of Puffs of Rescue Medication Per Day
NCT01709864 (15) [back to overview]	Percentage of Participants With a Clinically Important Improvement of >=4units in the SGRQ Total Score at Week 12
NCT01709864 (15) [back to overview]	Percentage of Days Without Rescue Medication Use
NCT01709864 (15) [back to overview]	Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing
NCT01709903 (9) [back to overview]	Analysis of FEV1 (L) Trough Response (Pre-dose) Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Superiority of QVA 110/50μg o.d. to Fluticasone/Salmeterol 500/50 μg b.i.d
NCT01709903 (9) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Non-inferiority of QVA149 110/50 μg o.d. to Fluticasone/Salmeterol 500/50 μg b.i.d
NCT01709903 (9) [back to overview]	Analysis of the TDI Focal Score Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Symptoms Reported Using E-diary Over 12 and 26 Weeks of Treatment
NCT01709903 (9) [back to overview]	Rescue Medication Use: Summary of the Mean Daily, Daytime and Nighttime Number of Puffs of Rescue Medication, by 4 Weekly Intervals
NCT01709903 (9) [back to overview]	Health Related Quality of Life Analysis of SGRQ Total Score After 26 Weeks of Treatment
NCT01709903 (9) [back to overview]	Analysis of Trough FVC (L) Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-4 Hours
NCT01712516 (11) [back to overview]	Percentage of Participants With a Clinically Important Improvement of at Least 4 Units in the SGRQ Total Score
NCT01712516 (11) [back to overview]	Secondary: Change From Baseline in Standardized FEV1 AUC (0-4 h), FEV1 AUC (4-8h), FEV1 AUC (8-12h) and FEV1 AUC (0-12 h)
NCT01712516 (11) [back to overview]	Secondary: Change From Baseline in Mean Total Daily Symptom Score, Mean Daytime Total Symptom Score and Mean Nighttime Total Symptom Score
NCT01712516 (11) [back to overview]	Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
NCT01712516 (11) [back to overview]	Change From Baseline in Pre-dose Trough FEV1
NCT01712516 (11) [back to overview]	Secondary: Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
NCT01712516 (11) [back to overview]	Change From Baseline in FEV1
NCT01712516 (11) [back to overview]	Change From Baseline in FVC
NCT01712516 (11) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score
NCT01712516 (11) [back to overview]	Change From Baseline in Trough FEV1
NCT01712516 (11) [back to overview]	Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h))
NCT01715298 (16) [back to overview]	Change From Baseline in Standardized Area Under The Curve for Forced Expiratory Volume in One Second for Different Time Spans Post Dosing
NCT01715298 (16) [back to overview]	Change From Baseline in Morning and Nighttime Symptom Scores
NCT01715298 (16) [back to overview]	Change From Baseline in Mean Trough Forced Vital Capacity
NCT01715298 (16) [back to overview]	Change From Baseline in Forced Vital Capacity at All Individual Timepoints
NCT01715298 (16) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second at All Individual Timepoints
NCT01715298 (16) [back to overview]	Change From Baseline in the Percentage of Days Without Rescue Medication Use
NCT01715298 (16) [back to overview]	Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire
NCT01715298 (16) [back to overview]	Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing
NCT01715298 (16) [back to overview]	Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing
NCT01715298 (16) [back to overview]	Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day
NCT01715298 (16) [back to overview]	Change From Baseline in Daily Symptom Scores
NCT01715298 (16) [back to overview]	Breathlessness Assessed by Transition Dyspnea Index
NCT01715298 (16) [back to overview]	"Change From Baseline in the Percentage of Nights With no Nighttime Awakenings"
NCT01715298 (16) [back to overview]	"Change From Baseline in the Percentage of Days With no Daytime Symptoms"
NCT01715298 (16) [back to overview]	"Change From Baseline in Percentage of Days Able to Perform Usual Daily Activities"
NCT01715298 (16) [back to overview]	Mean Trough Forced Expiratory Volume in One Second
NCT01727141 (11) [back to overview]	Change From Baseline in Pre-dose Trough FEV1
NCT01727141 (11) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
NCT01727141 (11) [back to overview]	Change From Baseline in Trough FEV1
NCT01727141 (11) [back to overview]	Change From Baseline in Standardized FEV1 AUC (0-4 h), FEV1 AUC (4-8h), FEV1 AUC (8-12h) and FEV1 AUC (0-12 h)
NCT01727141 (11) [back to overview]	Change From Baseline in Mean Total Daily Symptom Score, Mean Daytime Total Symptom Score and Mean Nighttime Total Symptom Score
NCT01727141 (11) [back to overview]	Change From Baseline in FVC
NCT01727141 (11) [back to overview]	Change From Baseline in FEV1
NCT01727141 (11) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score
NCT01727141 (11) [back to overview]	Percentage of Participants With a Clinically Important Improvement of at Least 4 Units in the SGRQ Total Score
NCT01727141 (11) [back to overview]	Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h))
NCT01727141 (11) [back to overview]	Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
NCT01748643 (6) [back to overview]	Subjective Evaluation of the View on the Operating Field by the Surgeon
NCT01748643 (6) [back to overview]	Peak Expiratory Flow
NCT01748643 (6) [back to overview]	Forced Vital Capacity
NCT01748643 (6) [back to overview]	Number of Intra-abdominal Pressure Rises > 18cmH2O
NCT01748643 (6) [back to overview]	Forced Expiratory Volume in 1 Second
NCT01748643 (6) [back to overview]	Duration of Surgery
NCT01854658 (6) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1
NCT01854658 (6) [back to overview]	Rescue Ventolin HFA Use
NCT01854658 (6) [back to overview]	Peak FEV1
NCT01854658 (6) [back to overview]	Onset of Action as Assessed by FEV1
NCT01854658 (6) [back to overview]	St. George Respiratory Questionnaire (SGRQ) Score
NCT01854658 (6) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks
NCT01922271 (7) [back to overview]	Residual Volume (RV)
NCT01922271 (7) [back to overview]	Inspiratory Capacity (IC)
NCT01922271 (7) [back to overview]	Functional Resistance Capacity (FRCpleth)
NCT01922271 (7) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2
NCT01922271 (7) [back to overview]	Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose
NCT01922271 (7) [back to overview]	Specific Airway Resistance (sRAW)
NCT01922271 (7) [back to overview]	Total Lung Capacity (TLC)
NCT01959516 (2) [back to overview]	Comparison of Glycopyrronium QD Versus Tiotropium QD on Symptoms Outcome
NCT01959516 (2) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment.
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
NCT01985334 (16) [back to overview]	Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
NCT01985334 (16) [back to overview]	Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
NCT01985334 (16) [back to overview]	Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
NCT01985334 (16) [back to overview]	Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
NCT01985334 (16) [back to overview]	Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
NCT01985334 (16) [back to overview]	Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
NCT01985334 (16) [back to overview]	Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
NCT02016885 (6) [back to overview]	Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4
NCT02016885 (6) [back to overview]	Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6
NCT02016885 (6) [back to overview]	Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 4
NCT02016885 (6) [back to overview]	Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6
NCT02016885 (6) [back to overview]	Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4
NCT02016885 (6) [back to overview]	Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4
NCT02129660 (7) [back to overview]	Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4
NCT02129660 (7) [back to overview]	Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6
NCT02129660 (7) [back to overview]	Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4
NCT02129660 (7) [back to overview]	Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4
NCT02129660 (7) [back to overview]	Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6
NCT02129660 (7) [back to overview]	Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4
NCT02129660 (7) [back to overview]	Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 6
NCT02196714 (38) [back to overview]	T 1/2
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Vd/F
NCT02196714 (38) [back to overview]	Vd/F
NCT02196714 (38) [back to overview]	Tmax
NCT02196714 (38) [back to overview]	Tmax
NCT02196714 (38) [back to overview]	T 1/2
NCT02196714 (38) [back to overview]	Lambda z
NCT02196714 (38) [back to overview]	Lambda z
NCT02196714 (38) [back to overview]	Cmax
NCT02196714 (38) [back to overview]	Cmax
NCT02196714 (38) [back to overview]	CL/F
NCT02196714 (38) [back to overview]	CL/F
NCT02196714 (38) [back to overview]	Change in QTc Fridericia's Interval From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	Change in QTc Bazett Interval From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	AUC 0-∞
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Glucose and Potassium Results (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in QT Interval From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	AUC 0-∞
NCT02196714 (38) [back to overview]	AUC 0-12
NCT02196714 (38) [back to overview]	AUC 0-12
NCT02196714 (38) [back to overview]	AUC 0-t
NCT02196714 (38) [back to overview]	Change in QRS Duration From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	AUC 0-t
NCT02196714 (38) [back to overview]	Change in Heart Rate From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in Mean Hematology Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02196714 (38) [back to overview]	Change in PR Interval From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	Change in QRS Axis From Pre-dose to 12 Hours Post Dose
NCT02196714 (38) [back to overview]	Change in Mean Chemistry Parameters (±SD) From Pre-dose to 12 Hours Post-dose
NCT02202616 (4) [back to overview]	Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4
NCT02202616 (4) [back to overview]	Single Point and Change in Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI)
NCT02202616 (4) [back to overview]	Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)
NCT02202616 (4) [back to overview]	Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Questionnaire (CAT)
NCT02233543 (2) [back to overview]	Percent of Time Spent During the Night Below 90 % in Blood Oxygen Saturation
NCT02233543 (2) [back to overview]	Mean Night-time Blood Oxygenation
NCT02236611 (1) [back to overview]	Change From Baseline in Trough FEV1 on Day 85
NCT02268396 (6) [back to overview]	Percentage of Devices in Agreement Between Laboratory-advanced Does Indicator Actuation and Weight-based Actuation Count at Last Available Visit.
NCT02268396 (6) [back to overview]	Percentage of Devices in Agreement Between Laboratory-Advanced Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit
NCT02268396 (6) [back to overview]	Percentage of Devices Where the Dose Indicator Actuation Count is >20 Less Than the Subject-reported Actuation Count (Undercount)
NCT02268396 (6) [back to overview]	Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count
NCT02268396 (6) [back to overview]	Percentage of Devices in Agreement Between eCRF-Based Dose Indicator Actuation Count and Weight-Based Actuation Count at the Last Available Visit
NCT02268396 (6) [back to overview]	Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count
NCT02276222 (10) [back to overview]	Percentage of Subjects With Treatment-emergent Serious Adverse
NCT02276222 (10) [back to overview]	Percentage of Subjects Who Discontinue the Study Due to TEAE
NCT02276222 (10) [back to overview]	Number of Subjects With Treatment-emergent Serious Adverse Events (SAE)
NCT02276222 (10) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAE)
NCT02276222 (10) [back to overview]	Percentage of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke
NCT02276222 (10) [back to overview]	Number of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke
NCT02276222 (10) [back to overview]	Incidence Rate Per 1000 Person Years of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke
NCT02276222 (10) [back to overview]	Number of Subjects Who Discontinue the Study Due to TEAE
NCT02276222 (10) [back to overview]	Mean Change From Baseline Over 48 Weeks in Trough FEV1 for All Subjects
NCT02276222 (10) [back to overview]	Percentage of Subjects With Treatment-emergent Adverse Events
NCT02343458 (17) [back to overview]	Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach
NCT02343458 (17) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach
NCT02343458 (17) [back to overview]	Change From Baseline in SGRQ Total Score at Week 24, US/China Approach
NCT02343458 (17) [back to overview]	Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach
NCT02343458 (17) [back to overview]	Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach
NCT02343458 (17) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.
NCT02343458 (17) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)
NCT02343458 (17) [back to overview]	TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population
NCT02343458 (17) [back to overview]	TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach
NCT02343458 (17) [back to overview]	TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population
NCT02343458 (17) [back to overview]	TDI Focal Score Over Weeks 12-24 Japan Approach
NCT02343458 (17) [back to overview]	FEV1 Measured at 5 Minutes Post-dose on Day 1
NCT02343458 (17) [back to overview]	Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach
NCT02343458 (17) [back to overview]	Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach
NCT02343458 (17) [back to overview]	FEV1 Measured at 15 Minutes Post-dose on Day 1
NCT02343458 (17) [back to overview]	Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach
NCT02343458 (17) [back to overview]	Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches
NCT02347072 (9) [back to overview]	Morning Pre-Dose Trough FEV1 on Day 30
NCT02347072 (9) [back to overview]	Morning Pre-Dose Trough FEV1 on Day 29
NCT02347072 (9) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24
NCT02347072 (9) [back to overview]	FEV1 AUC0-12
NCT02347072 (9) [back to overview]	Peak Change From Baseline in FEV1 Morning
NCT02347072 (9) [back to overview]	Peak Change From Baseline in IC (Inspiratory Capacity) Evening
NCT02347072 (9) [back to overview]	Peak Change From Baseline in IC Morning
NCT02347072 (9) [back to overview]	FEV1 AUC12-24
NCT02347072 (9) [back to overview]	Peak Change From Baseline in FEV1 Evening
NCT02347085 (9) [back to overview]	Morning Pre-Dose Trough FEV1 on Day 29
NCT02347085 (9) [back to overview]	FEV1 AUC12-24 on Day 29
NCT02347085 (9) [back to overview]	FEV1 AUC0-24 on Day 29
NCT02347085 (9) [back to overview]	Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29
NCT02347085 (9) [back to overview]	Peak Change From Baseline in IC Following the Morning Dose on Day 29
NCT02347085 (9) [back to overview]	Peak Change From Baseline in FEV1 on Day 29
NCT02347085 (9) [back to overview]	Peak Change From Baseline in FEV1 on Day 29
NCT02347085 (9) [back to overview]	Morning Pre-Dose Trough FEV1 on Day 30
NCT02347085 (9) [back to overview]	FEV1 AUC0-12 on Day 29
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1
NCT02371629 (15) [back to overview]	Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks
NCT02371629 (15) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Mean Daily COPD Symptom Score at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26
NCT02371629 (15) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death
NCT02371629 (15) [back to overview]	Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26
NCT02433834 (7) [back to overview]	Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15
NCT02433834 (7) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ-5) on Day 15
NCT02433834 (7) [back to overview]	FEV1 AUC0-3 on Day 15
NCT02433834 (7) [back to overview]	Change From Baseline in Average Daily Post-dose PEFR Over 14 Days
NCT02433834 (7) [back to overview]	Change From Baseline in Average Daily Pre-dose PEFR Over 14 Days
NCT02433834 (7) [back to overview]	Change From Baseline in Average Daily Rescue Medication Use Over 14 Days
NCT02433834 (7) [back to overview]	Change From Baseline in Morning Pre-dose Trough FEV1 on Day 15
NCT02487446 (8) [back to overview]	Change From Baseline in FEV1 AUC 0-4h, AUC 4-8h, AUC 8-12h, AUC 12-16h, AUC 16-20h and AUC 20-24h
NCT02487446 (8) [back to overview]	Change From Baseline in FEV1 AUC 0-12h
NCT02487446 (8) [back to overview]	Change From Baseline in Trough FEV1 (Mean of 23h 15 Minutes and 23 h 45 Minutes Post Previous Morning Dose)
NCT02487446 (8) [back to overview]	Change From Baseline in Pre-dose Trough FEV1 (Mean of 15 Minutes and 45 Minutes Pre Morning Dose)
NCT02487446 (8) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h
NCT02487446 (8) [back to overview]	Change From Baseline in FEV1 AUC 12-24h
NCT02487446 (8) [back to overview]	QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in Forced Vital Capacity (FVC) at Any Time Point
NCT02487446 (8) [back to overview]	QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in FEV1 at Any Time Point
NCT02487498 (8) [back to overview]	Change From Baseline in FEV1 AUC 0-12h
NCT02487498 (8) [back to overview]	Change From Baseline in FEV1 AUC 12-24h
NCT02487498 (8) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h
NCT02487498 (8) [back to overview]	QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in Pre-dose Trough FEV1 (Mean of 15 Minutes and 45 Minutes Pre Morning Dose)
NCT02487498 (8) [back to overview]	Superiority of QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in Trough FEV1 (Mean of 23h 15 Minutes and 23 h 45 Minutes Post Previous Morning Dose)
NCT02487498 (8) [back to overview]	Change From Baseline in FEV1 AUC 0-4h, AUC 4-8h, AUC 8-12h, AUC 12-16h, AUC 16-20h and AUC 20-24h
NCT02487498 (8) [back to overview]	QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in FEV1 at Any Time Point
NCT02487498 (8) [back to overview]	QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in Forced Vital Capacity (FVC) at Any Time Point
NCT02512302 (18) [back to overview]	Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
NCT02512302 (18) [back to overview]	Area Under the Curve From Time Zero to 24 Hours (AUC0_24)
NCT02512302 (18) [back to overview]	Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -
NCT02512302 (18) [back to overview]	Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate
NCT02512302 (18) [back to overview]	Cmax
NCT02512302 (18) [back to overview]	Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate
NCT02512302 (18) [back to overview]	Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101
NCT02512302 (18) [back to overview]	Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101
NCT02512302 (18) [back to overview]	Dose Normalized Cmax for Seebri and SUN-101.
NCT02512302 (18) [back to overview]	Area Under the Curve From Time Zero to Infinity (AUC0_infinity)
NCT02512302 (18) [back to overview]	Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101
NCT02512302 (18) [back to overview]	The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
NCT02512302 (18) [back to overview]	The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
NCT02512302 (18) [back to overview]	Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101
NCT02512302 (18) [back to overview]	Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate
NCT02512302 (18) [back to overview]	Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101
NCT02512302 (18) [back to overview]	Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate
NCT02512302 (18) [back to overview]	Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
NCT02524145 (2) [back to overview]	Central Command Regulation of Heart Rate
NCT02524145 (2) [back to overview]	Cardiac Beta-receptor Sensitivity
NCT02530281 (6) [back to overview]	Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4
NCT02530281 (6) [back to overview]	Percentage of Subjects Who Have a ≥2 Grade Improvement in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline at Week 4
NCT02530281 (6) [back to overview]	Median Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
NCT02530281 (6) [back to overview]	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4, Excluding Centers With Outlier Data
NCT02530281 (6) [back to overview]	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
NCT02530281 (6) [back to overview]	Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of ASDD Item #2 From Baseline at Week 4
NCT02530294 (5) [back to overview]	Median Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
NCT02530294 (5) [back to overview]	Percentage of Subjects Who Have a ≥2 Grade Improvement in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline at Week 4
NCT02530294 (5) [back to overview]	Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of Axillary Sweating Daily Diary (ASDD) Item #2 From Baseline at Week 4
NCT02530294 (5) [back to overview]	Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4
NCT02530294 (5) [back to overview]	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
NCT02553798 (4) [back to overview]	Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 44/ET
NCT02553798 (4) [back to overview]	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
NCT02553798 (4) [back to overview]	Long-term Safety Assessed Through Adverse Events and Local Skin Reactions
NCT02553798 (4) [back to overview]	Grade Improvement in Hyperhidrosis Disease Severity Scale (HDSS)
NCT02566031 (5) [back to overview]	Baseline Transitional Dyspnea Index (TDI) Focal Score
NCT02566031 (5) [back to overview]	Daily Rescue Medication Use (Number of Puffs)
NCT02566031 (5) [back to overview]	Trough Forced Expiratory Volume In One Second (FEV1) After 12 Weeks of Treatment
NCT02566031 (5) [back to overview]	Number of Participants With Change From Baseline on Total Score of COPD Assessment Test (CAT)
NCT02566031 (5) [back to overview]	Trough Forced Expiratory Volume In One Second (FEV1) After 4 Weeks of Treatment
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Ephinephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Postoperative Rise in Creatinine Levels
NCT02726620 (43) [back to overview]	Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Intraoperative Administration of Intravenous Fluids
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg
NCT02726620 (43) [back to overview]	In-hospital Mortality
NCT02726620 (43) [back to overview]	Estimated Intraoperative Blood Loss
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Epinephrine
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]	30-day Mortality
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Glycopyrrolate
NCT02860507 (2) [back to overview]	Operating Room (OR) Turnover Time When Using Sugammadex Instead of Combination of Neostigmine and Glycopyrrolate.
NCT02860507 (2) [back to overview]	Number of Patients Who Experience Postoperative Nausea and Vomiting, Post-operative Pain, and Post-operative Complications
NCT02867761 (14) [back to overview]	Treatment Failure Defined by Increase in Lower Respiratory Symptoms Necessitating Treatment With Active, Long-acting Inhaled Bronchodilator, Corticosteroids or Antibiotics
NCT02867761 (14) [back to overview]	Proportion of Individuals With Both a 4 Unit Improvement in SGRQ and a 1 Unit Improvement in BDI/TDI Without Treatment Failure
NCT02867761 (14) [back to overview]	Proportion of Individuals With a 2 Unit Improvement in CAT Without Treatment Failure
NCT02867761 (14) [back to overview]	Proportion of Individuals With a 1 Unit Improvement in the BDI/TDI Without Treatment Failure
NCT02867761 (14) [back to overview]	Proportion (Percentage) of Individuals Who Experience a 4 Unit Improvement in St. George's Respiratory Questionnaire (SGRQ) at 12 Weeks and do Not Meet Criteria for Treatment Failure During the 12 Week Treatment Period
NCT02867761 (14) [back to overview]	Mean Change in COPD Assessment Test (CAT)
NCT02867761 (14) [back to overview]	Mean Change in St. George's Respiratory Questionnaire (SGRQ)
NCT02867761 (14) [back to overview]	Symptoms and Rescue Medication Use Based on Daily Diary
NCT02867761 (14) [back to overview]	Area Under the Curve (AUC) 0-3 Hours for FEV1
NCT02867761 (14) [back to overview]	Change in FEF25-75%
NCT02867761 (14) [back to overview]	Change From Baseline in 12 Hour Trough Inspiratory Capacity - Absolute Value
NCT02867761 (14) [back to overview]	Change From Baseline in Trough FEV1 - % Predicted
NCT02867761 (14) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume Per 1 Second (FEV1) - Absolute Value
NCT02867761 (14) [back to overview]	Mean Change in Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI)
NCT02872935 (2) [back to overview]	Number of Participants Who Reported Nausea
NCT02872935 (2) [back to overview]	Number of Participants Who Experienced Vomiting.
NCT02948582 (15) [back to overview]	Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
NCT02948582 (15) [back to overview]	Percentage of Subjects With Treatment Emergent AEs
NCT02948582 (15) [back to overview]	t1/2; Plasma Half-life
NCT02948582 (15) [back to overview]	Tmax; Time to Maximum Observed Plasma Concentration
NCT02948582 (15) [back to overview]	Trough FEV1 (Change From Baseline)
NCT02948582 (15) [back to overview]	Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE
NCT02948582 (15) [back to overview]	Peak FEV1 (Change From Baseline and Percent Change)
NCT02948582 (15) [back to overview]	Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)
NCT02948582 (15) [back to overview]	AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
NCT02948582 (15) [back to overview]	Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).
NCT02948582 (15) [back to overview]	Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).
NCT02948582 (15) [back to overview]	Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
NCT02948582 (15) [back to overview]	Number of Clinically Significant Abnormal Laboratory Results Reported During the Study
NCT02948582 (15) [back to overview]	Cmax; Maximum Observed Plasma Concentration
NCT02948582 (15) [back to overview]	AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.
NCT02951312 (18) [back to overview]	Number of Subjects With Treatment Emergent AEs
NCT02951312 (18) [back to overview]	Number of Subjects Who Discontinued Due to AE
NCT02951312 (18) [back to overview]	Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
NCT02951312 (18) [back to overview]	Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
NCT02951312 (18) [back to overview]	Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
NCT02951312 (18) [back to overview]	Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
NCT02951312 (18) [back to overview]	Number of Subjects Who Died
NCT02951312 (18) [back to overview]	Peak FEV1 (Change From Baseline )
NCT02951312 (18) [back to overview]	Number of Subjects With Treatment Emergent SAEs
NCT02951312 (18) [back to overview]	Peak FEV1 (Percent Change)
NCT02951312 (18) [back to overview]	Percentage of Subjects With Treatment Emergent AEs
NCT02951312 (18) [back to overview]	t1/2 Plasma Half-life
NCT02951312 (18) [back to overview]	Tmax Time to Maximum Observed Plasma Concentration
NCT02951312 (18) [back to overview]	Trough FEV1 (Change From Baseline)
NCT02951312 (18) [back to overview]	FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)
NCT02951312 (18) [back to overview]	Cmax Maximum Observed Plasma Concentration
NCT02951312 (18) [back to overview]	AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration
NCT02951312 (18) [back to overview]	AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
NCT02996591 (16) [back to overview]	Numerical Rating Scale (NRS) Pain Scores at 1 Hour Postop
NCT02996591 (16) [back to overview]	Numerical Rating Scale Pain Scores at 2 Hours Postop
NCT02996591 (16) [back to overview]	Numerical Rating Scale Pain Scores on Postoperative Day (POD) 1
NCT02996591 (16) [back to overview]	Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)
NCT02996591 (16) [back to overview]	Opioid-Related Symptom Distress Scale (ORSDS) Score
NCT02996591 (16) [back to overview]	Time Until Patient is Ready for Discharge From Post-Anesthesia Care Unit (PACU) to Home.
NCT02996591 (16) [back to overview]	Back Pain on POD1
NCT02996591 (16) [back to overview]	Opioid Consumption
NCT02996591 (16) [back to overview]	Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)
NCT02996591 (16) [back to overview]	Cognitive Recovery at 2 Hours Post-operative
NCT02996591 (16) [back to overview]	Cognitive Recovery on POD1
NCT02996591 (16) [back to overview]	Incidence of Transient Neurologic Symptoms
NCT02996591 (16) [back to overview]	Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)
NCT02996591 (16) [back to overview]	Assessment of Patient Blinding to Group Assignment
NCT02996591 (16) [back to overview]	Opioid Consumption Through First Postoperative Day. Measured in mg OME
NCT02996591 (16) [back to overview]	Nausea Intensity
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Budesonide
NCT03075267 (42) [back to overview]	Terminal Elimination Rate Constant (λz) - Glycopyrronium
NCT03075267 (42) [back to overview]	Terminal Elimination Rate Constant (λz) - Formoterol
NCT03075267 (42) [back to overview]	Terminal Elimination Rate Constant (λz) - Budesonide
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Glycopyrronium
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Glycopyrronium
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Formoterol
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Formoterol
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Budesonide
NCT03075267 (42) [back to overview]	Maximum Plasma Concentration (Cmax) - Budesonide
NCT03075267 (42) [back to overview]	Elimination Half-life (t½) - Glycopyrronium
NCT03075267 (42) [back to overview]	Elimination Half-life (t½) - Formoterol
NCT03075267 (42) [back to overview]	Elimination Half-life (t½) - Budesonide
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Glycopyrronium
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Formoterol
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Budesonide
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Formoterol
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Budesonide
NCT03075267 (42) [back to overview]	Apparent Volume of Distribution (Vd/F) - Glycopyrronium
NCT03075267 (42) [back to overview]	Apparent Volume of Distribution (Vd/F) - Formoterol
NCT03075267 (42) [back to overview]	Apparent Volume of Distribution (Vd/F) - Budesonide
NCT03075267 (42) [back to overview]	Apparent Total Body Clearance (CL/F) - Glycopyrronium
NCT03075267 (42) [back to overview]	Apparent Total Body Clearance (CL/F) - Formoterol
NCT03075267 (42) [back to overview]	Apparent Total Body Clearance (CL/F) - Budesonide
NCT03075267 (42) [back to overview]	Accumulation Ratio for Cmax (RAC [Cmax]) - Glycopyrronium
NCT03075267 (42) [back to overview]	Accumulation Ratio for Cmax (RAC [Cmax]) - Formoterol
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium
NCT03075267 (42) [back to overview]	Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium
NCT03075267 (42) [back to overview]	Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol
NCT03075267 (42) [back to overview]	Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide
NCT03075267 (42) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Glycopyrronium
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Formoterol
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Formoterol
NCT03075267 (42) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Budesonide
NCT03075267 (42) [back to overview]	Accumulation Ratio for Cmax (RAC [Cmax]) - Budesonide
NCT03116997 (1) [back to overview]	Measure Participants' Recovery Time Post-Surgery
NCT03137784 (10) [back to overview]	Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment
NCT03137784 (10) [back to overview]	FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment
NCT03137784 (10) [back to overview]	FEV1 AUC (5 Min-1 h) After One Week of Treatment
NCT03137784 (10) [back to overview]	FEV1 AUC (5 Min-4 h) After One Week of Treatment
NCT03137784 (10) [back to overview]	Percent Change From Baseline in FEV1/FVC Ratio
NCT03137784 (10) [back to overview]	Trough FEV1 After One Week of Treatment, Point Estimate
NCT03137784 (10) [back to overview]	Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period
NCT03137784 (10) [back to overview]	Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment
NCT03137784 (10) [back to overview]	Trough Forced Vital Capacity (FVC) After 1 Week of Treatment
NCT03137784 (10) [back to overview]	Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment
NCT03138967 (3) [back to overview]	Overall Recovery Time
NCT03138967 (3) [back to overview]	PostOperative Complications
NCT03138967 (3) [back to overview]	Muscle Recovery Time
NCT03162055 (10) [back to overview]	Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population
NCT03162055 (10) [back to overview]	Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population
NCT03162055 (10) [back to overview]	Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks
NCT03162055 (10) [back to overview]	Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks
NCT03162055 (10) [back to overview]	Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1
NCT03162055 (10) [back to overview]	Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks
NCT03162055 (10) [back to overview]	Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks
NCT03162055 (10) [back to overview]	Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks
NCT03162055 (10) [back to overview]	Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks
NCT03162055 (10) [back to overview]	Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks
NCT03168308 (3) [back to overview]	Number of Hypoxic Episodes
NCT03168308 (3) [back to overview]	Number of Participants Who Needed Rescue Sugammadex After Initial Reversal of Neuromuscular Blockade
NCT03168308 (3) [back to overview]	Time to Complete Reversal of Neuromuscular Blockade
NCT03229486 (7) [back to overview]	Time to Regular Breathing
NCT03229486 (7) [back to overview]	Pediatric Anesthesia Emergence Delirium Score
NCT03229486 (7) [back to overview]	Time Recovery of TOF Ratio to 0.7
NCT03229486 (7) [back to overview]	Time Recovery of TOF Ratio to 0.8
NCT03229486 (7) [back to overview]	Time Recovery of TOF Ratio to 0.9
NCT03229486 (7) [back to overview]	Time to Awakening
NCT03229486 (7) [back to overview]	Time to Extubation
NCT03250182 (21) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium
NCT03250182 (21) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Formoterol
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Budesonide
NCT03250182 (21) [back to overview]	Time to Maximum Plasma Concentration (Tmax) - Budesonide
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Glycopyrronium
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Glycopyrronium
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Formoterol
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Formoterol
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Budesonide
NCT03250182 (21) [back to overview]	Maximum Plasma Concentration (Cmax) - Budesonide
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞) - Glycopyrronium
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Budesonide
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞) - Formoterol
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞) - Budesonide
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-tlast) - Glycopyrronium
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-tlast) - Formoterol
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-tlast) - Budesonide
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Glycopyrronium
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Glycopyrronium
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Formoterol
NCT03250182 (21) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC 0-12) - Formoterol
NCT03256552 (4) [back to overview]	Morning Pre-dose Trough FEV1
NCT03256552 (4) [back to overview]	Peak Change in FEV1
NCT03256552 (4) [back to overview]	FVC AUC0-2
NCT03256552 (4) [back to overview]	FEV1 AUC0-2
NCT03322657 (5) [back to overview]	Change of Diaphragmatic Contractility Speed- Sniff (Breathing From the Nose), cm/s
NCT03322657 (5) [back to overview]	Change of Diaphragmatic Contractility Speed, Deep Breathing From Mouth, cm/s
NCT03322657 (5) [back to overview]	TOF Ratio at 90 Min
NCT03322657 (5) [back to overview]	Time in Minutes to Reach Train of Four (TOF) Ratio ≥ 0.9 After the Administration of Reversal Agent
NCT03322657 (5) [back to overview]	The Time for Extubation After Administration of Reversal Agents
NCT03346057 (6) [back to overview]	Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]	Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]	Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346057 (6) [back to overview]	Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346057 (6) [back to overview]	Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03346070 (11) [back to overview]	Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346070 (11) [back to overview]	Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346070 (11) [back to overview]	Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis
NCT03346070 (11) [back to overview]	Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]	Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9
NCT03346070 (11) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]	Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03346070 (11) [back to overview]	Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis
NCT03346070 (11) [back to overview]	Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis
NCT03346070 (11) [back to overview]	Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis
NCT03346070 (11) [back to overview]	Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention
NCT03351608 (9) [back to overview]	Plasma Half-Life (t½) of Sugammadex [Part A]
NCT03351608 (9) [back to overview]	Time to Recovery of Participant Train-of-Four (TOF) Ratio to ≥0.9 [Part B]
NCT03351608 (9) [back to overview]	Time to Recovery of Participant TOF Ratio to ≥0.7 [Part B]
NCT03351608 (9) [back to overview]	Time to Recovery of Participant TOF Ratio to ≥0.8 [Part B]
NCT03351608 (9) [back to overview]	Plasma Clearance (CL) of Sugammadex [Part A]
NCT03351608 (9) [back to overview]	Percentage of Participants With ≥1 Adverse Event (AE) [Parts A and B]
NCT03351608 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of Sugammadex [Part A]
NCT03351608 (9) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to Infinity (AUC0-∞) of Sugammadex [Part A]
NCT03351608 (9) [back to overview]	Apparent Volume of Distribution (Vz) of Sugammadex [Part A]
NCT03357393 (7) [back to overview]	Assessment of Self-rated Patient Questionaries' Using S-PSR
NCT03357393 (7) [back to overview]	Bronchoscopist Evaluation Using a Likert-type Scale
NCT03357393 (7) [back to overview]	Discharge Assessment Using PADSS After 2 Hours Number of Patients Reaching PADSS Score 10 After 2 Hours
NCT03357393 (7) [back to overview]	Level of Sedation Using the Observer's Assessment of Alertness/Sedation (OAA/S) Scale
NCT03357393 (7) [back to overview]	Number of Participants With Interventions Performed
NCT03357393 (7) [back to overview]	Patients' Satisfaction Using a Likert-type Scale
NCT03357393 (7) [back to overview]	Quality of Recovery (QoR-23)
NCT03513757 (13) [back to overview]	Oral/Enteral Intake
NCT03513757 (13) [back to overview]	Nitrous Oxide
NCT03513757 (13) [back to overview]	Lidocaine Dose
NCT03513757 (13) [back to overview]	Irritability
NCT03513757 (13) [back to overview]	Delirium
NCT03513757 (13) [back to overview]	Dexmedetomidine Dose
NCT03513757 (13) [back to overview]	Discharge Ready
NCT03513757 (13) [back to overview]	Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion
NCT03513757 (13) [back to overview]	Eye Opening
NCT03513757 (13) [back to overview]	Glycopyrrolate Dose
NCT03513757 (13) [back to overview]	Total Propofol Administered
NCT03513757 (13) [back to overview]	Sevoflurane
NCT03513757 (13) [back to overview]	Sleep Pattern
NCT03742141 (1) [back to overview]	Frequency of Congruence of Nerve Integrity and Vocal Cord Functions
NCT03880266 (5) [back to overview]	Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2
NCT03880266 (5) [back to overview]	Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2
NCT03880266 (5) [back to overview]	Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2
NCT03880266 (5) [back to overview]	Mean Change From Baseline to Week 2 in Hand Sweating Severity Score
NCT03880266 (5) [back to overview]	Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2
NCT03939923 (5) [back to overview]	Heart Rate
NCT03939923 (5) [back to overview]	Blood Pressure (First Measurement of Systolic Blood Pressure Post Reversal)
NCT03939923 (5) [back to overview]	Peak Flow Rate
NCT03939923 (5) [back to overview]	Tidal Volume
NCT03939923 (5) [back to overview]	Time to Extubation

Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Transfer to the Recovery Room After Extubation

After anesthesia and prior to transfer to the recovery room after extubation, neuromuscular recovery was assessed by monitoring every 15 minutes the following clinical signs of recovery: level of consciousness (i.e., awake and oriented, arousable with minimal stimulation, responsive only to tactile stimulation); 5-second head lift test (ability to lift the head for 5 seconds); and general muscle weakness (NCT00451217)
Timeframe: Day 1

,,,

Intervention	Participants (Count of Participants)
	Consciousness: Awake and oriented	Consciousness: Arousable with minimal stimulation	Consciousness: Responsive only to tactile stimuli	Able to perform the 5 second head lift	Has general muscle weakness
Rocuronium + Neostigmine	35	13	0	37	9
Rocuronium + Sugammadex	30	16	2	38	3
Vecuronium + Neostigmine	26	14	5	32	6
Vecuronium + Sugammadex	29	17	2	40	4

Intervention	Minutes (Mean)
Rocuronium + Sugammadex	1.32
Rocuronium + Neostigmine	15.32
Vecuronium + Sugammadex	2.12
Vecuronium + Neostigmine	15.33

Intervention	Minutes (Mean)
Rocuronium + Sugammadex	1.62
Rocuronium + Neostigmine	26.78
Vecuronium + Sugammadex	4.47
Vecuronium + Neostigmine	23.43

Intervention	Minutes (Mean)
Rocuronium + Sugammadex	1.17
Rocuronium + Neostigmine	9.60
Vecuronium + Sugammadex	1.68
Vecuronium + Neostigmine	9.52

Intervention	Participants (Count of Participants)
	Prior to transfer to recovery room	Prior to discharge from recovery room
Rocuronium+Neostigmine	28	33
Rocuronium+Sugammadex	33	34
Vecuronium+Neostigmine	24	33
Vecuronium+Sugammadex	36	41

Intervention	Participants (Number)
	Responders	Non-Responders	Missing
Patients With Chronic Drooling	68	62	7

Intervention	Liters (Least Squares Mean)
	Day 1: -45 minutes	Day 1: -15 minutes	Day 1: 5 minutes	Day 1: 15 minutes	Day 1: 30 minutes	Day 1: 1 hour	Day 1: 2 hours	Day 1: 3 hours	Day 1: 4 hours	Day 1: 5 hours	Day 1: 23 hours 15 minutes	Day 1: 23 hours 45 minutes	Trough
NVA237 100 ug	1.24	1.26	1.35	1.41	1.45	1.48	1.52	1.53	1.52	1.49	1.37	1.39	1.38
NVA237 12.5 ug	1.25	1.25	1.30	1.36	1.41	1.42	1.44	1.43	1.41	1.39	1.27	1.29	1.28
NVA237 25 ug	1.24	1.26	1.34	1.41	1.44	1.46	1.48	1.48	1.45	1.43	1.29	1.31	1.30
NVA237 50 ug	1.24	1.25	1.34	1.41	1.44	1.46	1.50	1.49	1.49	1.44	1.36	1.37	1.36
Placebo	1.24	1.26	1.26	1.27	1.28	1.28	1.31	1.30	1.30	1.28	1.24	1.25	1.24
Tiotropium Bromide	1.25	1.25	1.31	1.35	1.40	1.41	1.45	1.46	1.46	1.45	1.35	1.37	1.36

Intervention	Liters (Least Squares Mean)
NVA237 12.5 ug	1.317
NVA237 25 ug	1.333
NVA237 50 ug	1.374
NVA237 100 ug	1.385
Placebo	1.243
Tiotropium Bromide	1.370

Intervention	Participants (Number)
	Total number of patients with any AE	Total number with any significant AE
NVA237 100 µg	26	3
NVA237 200 µg	26	4
Placebo	24	6

Intervention	Liters (Least Squares Mean)
	Trough FEV1 Day 1	Trough FEV1 Day 28
NVA237 100 µg	1.465	1.502
NVA237 200 µg	1.480	1.492
Placebo	1.334	1.341

Intervention	milliseconds (Least Squares Mean)
	30 minutes	2 hours
Indacaterol 300 μg	-1.3	-1.6
Indacaterol/Glycopyrrolate 150/100 μg	0.5	1.6
Indacaterol/Glycopyrrolate 300/100 μg	-0.9	-1.2
Indacaterol/Glycopyrrolate 600/100 μg	4.1	2.6
Placebo	-2.2	-2.8

Intervention	milliseconds (Least Squares Mean)
	30 minutes	4 hours	23 hours 45 minutes
Indacaterol 300 μg	-1.2	-2.6	-3.6
Indacaterol/Glycopyrrolate 150/100 μg	1.6	3.1	0.4
Indacaterol/Glycopyrrolate 300/100 μg	-0.6	-0.1	-2.9
Indacaterol/Glycopyrrolate 600/100 μg	2.4	2.8	0.5
Placebo	0.2	-0.1	-1.6

Intervention	beats per minute (Least Squares Mean)
Indacaterol/Glycopyrrolate 600/100 μg	-0.113
Indacaterol/Glycopyrrolate 300/100 μg	0.787
Indacaterol/Glycopyrrolate 150/100 μg	-0.230
Indacaterol 300 μg	0.240
Placebo	0.170

Intervention	beats per minute (Least Squares Mean)
Indacaterol/Glycopyrrolate 600/100 μg	-2.877
Indacaterol/Glycopyrrolate 300/100 μg	-2.770
Indacaterol/Glycopyrrolate 150/100 μg	-0.547
Indacaterol 300 μg	-1.849
Placebo	-0.329

Intervention	Liters (Least Squares Mean)
	Day 1	Day 14
Indacaterol 300 μg	1.44	1.46
Indacaterol/Glycopyrrolate 150/100 μg	1.50	1.50
Indacaterol/Glycopyrrolate 300/100 μg	1.51	1.52
Indacaterol/Glycopyrrolate 600/100 μg	1.59	1.61
Placebo	1.27	1.31

Intervention	Liters (Least Squares Mean)
	Day 1	Day 14 (n=42, 45, 44, 48, 47)
Indacaterol 300 μg	2.924	2.901
Indacaterol/Glycopyrrolate 150/100 μg	3.000	2.952
Indacaterol/Glycopyrrolate 300/100 μg	3.029	3.042
Indacaterol/Glycopyrrolate 600/100 μg	3.151	3.134
Placebo	2.634	2.726

Intervention	Liters (Least Squares Mean)
Indacaterol/Glycopyrrolate 300/50 μg	1.512
Indacaterol 300 μg	1.389
Indacaterol 600 μg	1.395
Placebo	1.286

Intervention	Liters (Least Squares Mean)
Indacaterol/Glycopyrrolate 300/50 μg	1.610
Indacaterol 300 μg	1.473
Indacaterol 600 μg	1.457
Placebo	1.317

Intervention	Participants (Number)
	Serious Adverse Events	Adverse Events	Discontinuations Due to Adverse Events
Indacaterol 300 μg	0	31	0
Indacaterol 600 μg	0	37	2
Indacaterol/Glycopyrrolate 300/50 μg	2	39	3
Placebo	0	31	0

Intervention	Participants (Number)
	Overall Adverse Events	Serious Adverse Events (SAEs)
NVA237 50μg	2	0
Placebo	4	0

Intervention	Liters (Least Squares Mean)
	Day 1, minute 5 (n=495, 255, 253)	Day 1, minute 15 (n=502, 255, 254)	Day 1, minute 30 (n=507, 252, 254)	Day 1, hour 1 (n=511, 256, 254)	Day 1, hour 2 (n=513, 253, 252)	Day 1, hour 3 (n=510, 248, 252)	Day 1, hour 4 (n=504, 239, 250)	Day 1, hour 23, minute 15 (n=481, 243, 239)	Day 1, hour 23, minute 45 (n=474, 239, 232)	Day 15, minute 5 (n=498, 223, 243)	Day 15, minute 15 (n=487, 229, 239)	Day 15, minute 30 (n=503, 233, 242)	Day 15, hour 1 (n=501, 229, 240)	Week 5, minute 5 (n=476, 221, 231)	Week 5, minute 15 (n=479, 222, 234)	Week 5, minute 30 (n=480, 223, 234)	Week 9, minute 5 (n=454, 217, 227)	Week 9, minute 15 (n=459, 220, 225)	Week 9, minute 30 (n=460, 220, 226)	Week 12, minute 5 (n=453, 212, 230)	Week 12, minute 15 (n=448, 205, 222)	Week 12, minute 30 (n=455, 212, 226)	Week 12, hour 1 (n=455, 210, 227)	Week 12, hour 2 (n=446, 207, 225)	Week 12, hour 3 (n=444, 204, 225)	Week 12, hour 4 (n=437, 202, 224)	Week 12, hour 23, minute 15 (n=430, 200, 214)	Week 12, hour 23, minute 45 (n=426, 195, 205)	Week 16, minute 5 (n=429, 207, 218)	Week 16, minute 15 (n=428, 209, 219)	Week 16, minute 30 (n=433, 209, 220)	Week 20, minute 5 (n=430, 206, 218)	Week 20, minute 15 (n=430, 207, 220)	Week 20, minute 30 (n=431, 207, 221)	Week 26, minute 5 (421, 202, 213)	Week 26, minute 15 (n=414, 200, 207)	Week 26, minute 30 (n=424, 206, 213)	Week 26, hour 1 (n=425, 206, 212)	Week 26, hour 2 (n=420, 203, 208)	Week 26, hour 3 (n=416, 204, 213)	Week 26, hour 4 (n=416, 203, 208)	Week 26, hour 23, minute 15 (n=405, 187, 202)	Week 26, hour 23, minute 45 (n=401, 185, 198)	Week 34, minute 5 (n=408, 194, 212)	Week 34, minute 15 (n=407, 191, 214)	Week 34, minute 30 (n=410, 196, 215)	Week 34, hour 1 (n=412, 195, 215)	Week 42, minute 5 (n=398, 189, 199)	Week 42, minute 15 (n=405, 188, 201)	Week 42, minute 30 (n=405, 189, 201)	Week 50, minute 5 (n=386, 185, 199)	Week 50, minute 15 (n=391, 187, 203)	Week 50, minute 30 (n=392, 186, 204)	Week 52, minute 5 (n=401, 188, 197)	Week 52, minute 15 (n=394, 183, 200)	Week 52, minute 30 (n=402, 189, 202)	Week 52, hour 1 (n=404, 190, 201)	Week 52, hour 2 (n=402, 186, 202)	Week 52, hour 3 (n=400, 186, 199)	Week 52, hour 4 (n=397, 184, 199)	Week 52, hour 23, minute 15 (n=388, 183, 198)	Week 52, hour 23, minute 45 (n=395, 185, 199)
Glycopyrronium Bromide 50 μg	2.915	2.982	3.004	3.074	3.119	3.129	3.076	2.926	2.930	2.984	3.016	3.028	3.068	3.004	3.024	3.085	3.047	3.050	3.079	2.991	3.003	2.985	3.062	3.093	3.129	3.050	2.991	2.977	3.016	3.029	3.063	2.985	3.020	3.058	2.956	2.980	2.983	3.034	3.049	3.097	3.022	2.971	2.952	2.967	2.983	3.002	3.014	2.982	3.001	3.016	2.925	2.971	2.999	2.899	2.942	2.923	2.992	2.997	3.029	2.984	2.866	2.869
Placebo to Glycopyrronium Bromide	2.731	2.719	2.692	2.732	2.762	2.811	2.767	2.745	2.749	2.760	2.748	2.756	2.757	2.768	2.771	2.804	2.767	2.764	2.768	2.726	2.735	2.707	2.741	2.801	2.839	2.793	2.799	2.799	2.753	2.737	2.747	2.744	2.749	2.774	2.733	2.713	2.715	2.721	2.777	2.831	2.776	2.758	2.759	2.713	2.718	2.690	2.711	2.727	2.713	2.734	2.729	2.729	2.731	2.673	2.701	2.666	2.696	2.727	2.742	2.725	2.675	2.694
Tiotropium 18 μg	2.856	2.903	2.937	2.975	3.033	3.073	3.031	2.923	2.923	2.980	3.030	3.018	3.023	3.011	3.024	3.063	3.029	3.046	3.079	2.978	3.004	2.987	3.048	3.065	3.096	3.054	2.985	2.946	3.009	3.002	3.036	2.966	2.994	3.028	2.945	2.959	2.949	2.997	3.036	3.065	3.021	2.901	2.883	2.919	2.948	2.947	2.959	2.983	3.001	3.021	2.942	2.962	2.998	2.916	2.969	2.962	3.011	3.005	3.020	2.991	2.865	2.868

glycopyrrolate

Description

Cross-References

Synonyms (138)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (163)

Molecular Functions (40)

Ceullar Components (37)

Bioassays (77)

Research

Studies (1,109)

Market Indicators

Research Demand Index: 96.72

Study Types

Clinical Trials (186)

Trial Overview

Trial Outcomes

Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Transfer to the Recovery Room After Extubation

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8

Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Discharge From the Recovery Room

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9.

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium

Number of Participants Able to Perform a 5-second Head Lift

Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)

Number of Participants Experiencing General Muscle Weakness

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium

Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS)

Parent/Caregiver's Global Assessment of Treatment

Investigator's Global Assessment of Treatment

Parent/Caregiver's Assessment of the Extent of Drooling Using Visual Analog Scale (VAS)

Parent/Caregiver's Assessment of the Extent of Drooling Using VAS

Least Squares Means of FEV1 (L) at Day 1, by Timepoint

Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment

Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Least Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day

Change From Baseline in QTc (Fridericia's Formula) at Day 7

Change From Baseline in QTc (Fridericia's Formula) at Day 14

Change From Baseline in QTc (Fridericia's Formula) at Day 1

Change From Baseline in Mean 24 Hour Heart Rate at Day 14

Change From Baseline in Mean 24 Hour Heart Rate at Day 1

Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14

Trough Forced Vital Capacity (FVC) at Day 1 and Day 14

Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7

Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve (AUC) 5 Minutes-12 Hours at Day 7

Number of Participants With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events

Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14

Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14

Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14

Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)

Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52

Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52

Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52

Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)

"Percentage of Days Able to Perform Usual Daily Activities During the Study (Baseline to Week 52)"

"Percentage of Days With no Daytime Symptoms During the Study (Baseline to Week 52)"

"Percentage of Nights With no Nighttime Awakenings During the Study (Baseline to Week 52)"

Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)

Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)

Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52

Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)

Intervention	Liters (Least Squares Mean)
	Day 1	Week 26 (n=451, 219, 233)	Week 52 (n=416, 196, 210)
Glycopyrronium Bromide 50 μg	1.478	1.458	1.412
Placebo to Glycopyrronium Bromide	1.388	1.324	1.303
Tiotropium 18 μg	1.471	1.408	1.392

Intervention	Liters (Least Squares Mean)
	Day 1	Week 12 (n=442, 204, 217)	Week 26 (n=418, 196, 208)	Week 52 (n=395, 186, 201)
Glycopyrronium Bromide 50 μg	2.936	2.985	2.962	2.866
Placebo to Glycopyrronium Bromide	2.757	2.802	2.758	2.687
Tiotropium 18 μg	2.930	2.970	2.892	2.866

Intervention	Exacerbations per treatment year (Number)
Glycopyrronium Bromide 50 μg	0.54
Placebo to Glycopyrronium Bromide	0.80
Tiotropium 18 μg	0.62

Intervention	Percentage of days (Least Squares Mean)
Glycopyrronium Bromide 50 μg	38.02
Placebo to Glycopyrronium Bromide	36.18
Tiotropium 18 μg	38.09

Intervention	Percentage of days (Least Squares Mean)
Glycopyrronium Bromide 50 μg	6.54
Placebo to Glycopyrronium Bromide	3.81
Tiotropium 18 μg	7.14

Intervention	Percentage of nights (Least Squares Mean)
Glycopyrronium Bromide 50 μg	57.36
Placebo to Glycopyrronium Bromide	52.15
Tiotropium 18 μg	55.47

Intervention	Puffs (Least Squares Mean)
Glycopyrronium Bromide 50 μg	-1.58
Placebo to Glycopyrronium Bromide	-1.20
Tiotropium 18 μg	-1.83

Intervention	Units on a scale (Least Squares Mean)
Glycopyrronium Bromide 50 μg	-1.85
Placebo to Glycopyrronium Bromide	-1.42
Tiotropium 18 μg	-1.87

Intervention	Units on a scale (Least Squares Mean)
Glycopyrronium Bromide 50 μg	40.85
Placebo to Glycopyrronium Bromide	44.16
Tiotropium 18 μg	41.32

Intervention	Percentage of participants (Number)
Glycopyrronium Bromide 50 μg	32.8
Placebo to Glycopyrronium Bromide	40.2
Tiotropium 18 μg	30.1